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1. Abbreviations 
AC Adenylyl cyclase 
ATP Adenosine triphosphate 
5-LOX Arachidonate 5-lipoxygenase 
cAMP cyclic adenosine monophosphate 
CIN Cervical intraepithelial neoplasia  
COX Cyclooxygenase 
COXibs COX-2 inhibitors 
CRP C-reactive protein 
DFS Disease-free survival 
EC Endometrial cancer 
ECM Extracellular matrix 
EGFR Epidermal growth factor receptor 
EGR1 Early growth response protein 1  
ELISA Enzyme-linked immunosorbent assay 
EP3 Prostaglandin E2 receptor 3 
FGF2 Fibroblast growth factor 2 
Gi G protein alpha inhibitor 
Gs G protein alpha stimulator  
HPV Human papillomavirus  
IFN-γ interferon-γ 
IL-1β Interleukin-1β 
IL-6 Interleukin 6  
LRP Low density lipoprotein receptor-related protein 
MAPK Mitogen-activated protein kinase cascade  
MMP Matrix metalloproteinase 
mPGES-1 microsomal PGE synthase-1 
mTORC1  mammalian target of rapamycin complex 1  
NSAIDs Nonsteroidal anti-inflammatory drugs 
OS Overall survival 
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PAI-1 Plasminogen activator inhibitor type 1 
p-ERK1/2 phosphorylated extracellular signal-regulated kinases 1/2 
PGE2 Prostaglandin E2 
PGES Prostaglandin G synthase 
PGH2 Prostaglandin H2 
PI3-k/Akt phosphatidylinositol 3-kinase/protein kinase B 
PLA2 Phospholipases A2 
PPAR β/δ Peroxisome proliferator-activated receptor β/δ 
RM Recurrent miscarriages 
ROCK Rho-associated coiled-coil kinase 
RT-PCR Rualitative reverse transcription-polymerase chain reaction  
RXR Retinoid X receptor  
STAT Signal transducers and activators of transcription 
SUMO-1 Small ubiquitin-like modifier-1 
TGF-β1 transforming growth factor β1  
TNF Tumor necrosis factor 
TP Thymidine phosphorylase  
tPA tissue-type plasminogen activator  
uPA urokinase-type plasminogen activator 
uPAR urokinase-type plasminogen activator receptor 
uRPL unexplained recurrent pregnancy losses 
USF1/2 Upstream stimulatory factor proteins 1/2  
VEGF Vascular endothelial growth factor 
VDR Vitamin D receptor 
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2. Introduction 
Abundant literature has demonstrated a strong correlation between chronic inflammation 
and cancer development since chronic inflammation contributes to the development of over 
15% of malignancies worldwide1. Plenty of pro-inflammatory factors mediate a role in 
carcinogenesis, such as tumour necrosis factor (TNF), interleukin (IL)-1α, IL-1β, IL-6, IL-8, IL-
18, matrix metallopeptidase-9 (MMP-9), vascular endothelial growth factor (VEGF), 
cyclooxygenase 2 (COX-2), and arachidonate 5-lipoxygenase (5-LOX)2. Serum levels of C-
reactive protein (CRP), IL-6, and IL-1 receptor antagonist (IL-1Ra) are significantly associated 
with endometrial cancer risk when analyzing 246,000 women in ten European countries3. 
The signaling of cyclooxygenase 2-prostaglandin E2-prostaglandin E2 receptors (COX-2-PGE2-
EPs) is the central inflammatory pathway involved in the carcinogenesis. Based on the 
current information, this doctoral thesis aimed to supplement some additional knowledge in 
the carcinogenesis of cervical cancer and the pathology of recurrent miscarriage from the 
perspective of inflammation. 
2.1 Biogenesis and signaling: COX-2-PGE2-EPs  
Arachidonic acid is released from the membrane phospholipids by phospholipase A2 (PLA2) 
and then metabolized by the enzyme of COX-1 and COX-2 into prostaglandin H2 (PGH2). PGH2 
is converted by specific isomerases (PGDS, PGES, PGFS and PGIS) and TXA synthase to 
various prostaglandins (PGE2, PGD2, PGF2α, PGI2) and the thromboxane A2 (TxA2)4 (Figure 1). 
All these prostaglandins (PGE2, PGD2, PGF2α, PGI2 and TXA2) act through relative specific G-
protein coupled receptors (GPCR) to mediate their effects, referred to as the EP, DP, FP, IP 
and TP receptors5 (Figure 1).  
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Figure1. COX-2- PGE2 -EPs signaling pathway. Arachidonic acid is released from the membrane 
phospholipids by PLA2 and then is metabolized by COX-1 and COX-2 into PGH2. PGH2 is converted by 
specific isomerases (PGDS, PGES, PGFS and PGIS) and TXA synthase to multiple prostaglandins (PGE2, 
PGD2, PGF2α, PGI2) and the thromboxane A24. Prostaglandins act through relative receptors (EP, DP, 
FP, IP and TP) to mediate their effects5. The inhibitors of COX-2- PGE2 -EPs signaling pathway include 
nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 selective inhibitors (COXIBs), PGES inhibitor, 
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and EP inhibitors. NSAIDs inhibit the function of 
both COX-1 and COX-2 while COXIBs only inhibit the function of COX-2. PGE2 is degraded by 15-PGDH 
into an inactive 15-keto PGE2 after binding to EP receptors6. Both PGES inhibitors and EP inhibitors 
are novel inhibitors that have been investigating in these years. Abbreviation: PLA2, phospholipases 
A2; COX-1, cyclooxygenase-1 COX-2, cyclooxygenase-2; PGDS, prostaglandin D synthase; PGES, 
prostaglandin G synthase; PGFS, prostaglandin F synthase; PGIS, prostaglandin I synthase; PG, 
prostaglandin; EP prostaglandin E receptor; DP1.2, prostaglandin D receptor 1.2; FP, prostaglandin F 
receptor; IP, prostaglandin I receptor; ATP, adenosine triphosphate; cAMP, cyclic adenosine 
monophosphate. 
 
                                                                                                                                                                
Introduction  
5 
 
    COX enzymes are the primary enzymes in the synthesis of eicosanoids and exist in two 
isoforms: COX-1 is considered to be ubiquitously expressed7, whereas COX-2 is expressed 
predominantly in inflammatory cells and upregulated in chronic and acute inflammations8. 
COX-1 and COX-2 are located on human chromosomes 9 and 1 respectively9. PGs produced 
by COX-1 are crucial for maintaining the integrity of gastric mucosa, normal platelet 
aggregation and renal function, while PGs derived by COX-2 contributes to cancer 
progression and metastasis10. The COX-2 expression is stimulated by different growth factors, 
cytokines and prostaglandins, which is associated with inflammatory response and is seen as 
a prognostic factor for malignancy11,12. Furthermore, upregulation of COX-2 and PGE2 has 
been identified in many human cancers and precancerous lesions, and COX inhibitory drugs 
show a protective effects in colorectal cancer and breast cancer13. 
    The three distinct synthases contributing to PGE2 synthesis are consist of microsomal PGE 
synthase-1 (mPGES-1), mPGES-2 and cytosolic PGE synthase (cPGES)14,15. There are two 
separate PGE2-biosynthetic routes: the cPLA2-COX-1-cPGES and cPLA2-COX-2-mPGES 
pathways15. COX-2 linked to mPGES is essential for delayed PGE2 biosynthesis, which may be 
linked to inflammation, fever, osteogenesis, and cancer15. mPGES-1 is primarily responsible 
for increasing PGE2 levels during inflammation and carcinogenesis, and elevated levels of  
mPGES-1 present in a number of human cancers, such as colon, lung, stomach, pancreas, 
cervix, prostate and head and neck squamous carcinoma16. 
    PGE2 is the most abundant prostaglandin in humans and is known as a key mediator in 
inflammation. The functions of PGE2 are mainly facilitated by specific membrane-bound G-
protein-coupled EP receptors (EP1-EP4) with various signaling pathways. EP1 is coupled to 
the G protein alpha q (Gq) to mobilize intracellular Ca2+, EP2 and EP4 are coupled to the G 
protein alpha stimulator (Gs) to activate adenylyl cyclase (AC), and EP3 is mainly coupled to 
the G protein alpha inhibitor (Gi) to suppress AC17. The EP3 receptor can also be coupled to 
G12/13 proteins, resulting in the activation of the small G protein Rho18. After binding its 
receptor, PGE2 can be catalyzed by 15-hydroxyprostaglandin dehydrogenase (15-PGDH) into 
an inactive 15-keto PGE26.  
    In cancer development, EP1 mediates tumor cell migration, invasion and adjustment to 
hypoxia enviroment; EP2 induces angiogenesis and suppresses the anti-tumor immune 
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response; EP4 can mediate tumor cell migration, metastasis, as well as promote aberrant 
DNA methylation in colon cancer18. The role of EP3 in carcinogenesis is still unclear with 
conflicting effects in distinct cancer cells. EP3 is a unique PGE2 receptor, since the human EP3 
gene consists of ten exons and nine introns, encoding at least eight distinct EP3 splice 
variants19. EP3 isoforms differ in the amino acid sequences in their specific C-terminal tails 
and signal transduction pathways by activating different second messengers20,21. This might 
increase the complexity of investigating the effects of EP3 on the pathological mechanism of 
cancer development.  
2.2 Crosstalks with other signaling pathways in cancer 
Wang et al. elucidated crosstalks interacting with COX-2-PGE2-EPs signaling pathways in 
carcinogenesis, mainly consisting of the epidermal growth factor receptor (EGFR) pathway, 
nuclear receptor pathway, and Ras-mitogen-activated protein kinase cascade (Ras-MAPK) 
pathway7. The classic and most studied signaling pathway is EGFR pathway, since both COX-2 
and PGE2 are involved in the proliferation, migration and invasion of human colon carcinoma 
cells through EGFR22,23. Combining EGFR tyrosine kinase inhibitor (erlotinib) with COX-2 
inhibitor (celecoxib) can inhibit the tumor cells proliferation of head and neck cancer cell 
lines and the tumor growth of nude mouse xenograft models compared with either single 
agent24. Moverover, the biomarker expression (antigen Ki67, phosphorylated S6 and CD34) 
of head and neck cancer is decreased in 11 cancer patients received the combined treatment 
with erlotinib and celecoxib24. PGE2 can also trans-activate peroxisome proliferator activated 
receptor β/δ (PPAR β/δ) via phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) 
signaling to promote cell survival of intestinal adenoma25. In the mice model, PGE2 can 
stimulate tumor growth of intestinal adenoma in Apcmin mice, but not in Apcmin mice lacking 
PPAR β/δ25. As a nuclear transcription factor, PPAR β/δ binds as heterodimers with a retinoid 
X receptor (RXR) for transcription initiation26, and the natural ligands for PPAR β/δ include 
fatty acid and PGE227. Additionally, PGE2 activates Ras-MAPK cascade and high expression of 
PGE2 can induce COX-2 expression in intestinal adenomas28. Studies concerning the COX-2-
PGE2-EPs signaling pathway is limited in gynecological cancers compared with that in 
gastrointestinal cancer and breast cancer29. 
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2.3 Endometrial cancer 
Endometrial cancer (EC) is the most common gynecological malignancy in developed 
countries, including the United States, Canada and Western Europe30. There estimated to be 
more than 61,000 new cases of EC and over 10,000 deaths in the United States according to 
the 2017 cancer statistics31. The main risk factor for EC is exposure to endogenous and 
exogenous estrogens, which is linked to obesity, diabetes, early age at menarche, null parity, 
late menopause and use of tamoxifen32. EC is classified into two subtypes: type I and type II. 
Type I is the most common subtype, and it is low-grade, endometrioid, diploid, hormone-
receptor-positive endometrial cancer with a good prognosis32. By contrast, type II EC is high-
grade, non-endometrioid, aneuploidy, hormone-receptor-negative, TP53-mutated with a 
poor prognosis and a higher risk of metastasis32.  
2.3.1 COX-2 and endometrial cancer 
COX-2 is expressed in the cytoplasm of normal proliferative glandular epithelium and 
endometrial cancer cells33. The mRNA level of COX-2 is elevated in 51 cancerous endometria 
compared with 16 normal endometria34. COX-2 is proved to be a negative predictor of 
disease relapse for EC patients in the univariate analysis. COX-2 plays a key role not only in 
the maintenance of the endometrium during the menstrual cycle but also in EC 
carcinogenesis35. COX-2 overexpression increases angiogenesis, migration, invasiveness and 
tumor-induced immmunosuppression, as well as prevents apoptosis35. A combined 
treatment with celecoxib (a COX-2 inhibitor) and rapamycin (a mammalian target of 
rapamycin complex 1 inhibitor, a mTORC1 inhibitor) reduces EC progression in mouse 
models of EC and human EC cell lines36. Brasky et al. demonstrated that treatment of aspirin 
could reduce the risk of EC, especially in estrogen-mediated cases by analyzing 22,268 
female Americans after up to ten years37. In clinical studies, the correlation of COX-2 
expression and EC patients’ prognosis still remains conflicting38,39. PGE2 is associated with 
both endometrial functions and disorders. Ke et al. found that prostaglandin E synthase 2 
(PTGES2) is upregulated in the 119 endometrial cancer tissues compared with 50 normal 
endometria, and PTGES2 is associated with the endometrial carcinoma stage, grade and the 
depth of myometrial invasion40. 
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2.3.2 EPs expression in healthy normal endometrium 
The expressions of EP receptors vary during different phases of normal endometrium. EP1 
peaks during the early secretory phase and EP2-4 peak during the mid-secretory phase 
across the regular human menstrual cycle by reverse transcription polymerase chain 
reaction (RT-PCR)41. Besides, EP1 is located in different regions of glands depending on 
different phases41. However, Zhu et al. (2017) found that EP1 is expressed highly during the 
proliferative phase and decreases sharply during the early secretory phase in both 
epithelium and stroma cells of the normal endometrium with the method of 
immunohistochemistry42. Both studies indicate that EP1 may be regulated by sex hormones 
and may also play a role in mediating implantation.  
2.3.3 EPs expression in endometrial cancer 
Zhu et al. suggested that six patients with higher EP1 staining survived after seven years 
follow-up, although EP1 expression was not correlated to progression free survival or overall 
survival of endometrial cancer patients42. The biosynthesis of EP2, EP4 and cAMP are 
significantly elevated in response to PGE2 in endometrial adenocarcinoma tissues compared 
with normal endometria by quantitative PCR43. PGE2 stimulates vascular endothelial growth 
factor (VEGF) expression in Ishikawa cells (a human endometrial adenocarcinoma cell line) 
via EP2-cAMP-mediated transactivation of the epidermal growth factor receptor (EGFR) and 
extracellular signal-regulated kinases 1/2 (ERK1/2) pathways44. Battersby and his colleagues 
proved that PGE2 upregulates the expression of fibroblast growth factor 2 (FGF2) via the EP2 
receptor in a cAMP-, c-Src-, epidermal growth factor receptor (EGFR)- and extracellular 
signal-regulated kinase (ERK)-dependent manner in Ishikawa cells45. FGF2 is a potent 
mitogenic and angiogenic factor, causing adenocarcinoma cell proliferation in nude mice 
transplanted subcutaneously with endometrial adenocarcinoma46. PGE2 can enhance 
proliferation and invasion of two human endometrial cancer cells (Ishikawa and HEC-1B) by 
stimulating EP4 receptor and small ubiquitin-like modifier-1 (SUMO-1) via the Wnt/β-catenin 
signaling pathway40. 
    The proliferation and angiogenesis of implanted tumor can be directly inhibited in EP3-/- 
mice, as well as suppressed by an EP3 antagonist (ONO-AE3–240) in wild-type mice47. EP3 
                                                                                                                                                                
Introduction  
9 
 
mRNA is expressed abundantly in the uterus48. The latest study by our research group 
demonstrated that high expression of EP3 correlates with poor progression-free survival and 
overall survival in endometrial carcinoma49. Our group also proved that L-798,106 (a specific 
EP3 antagonist) induces the expression of estrogen receptor β and inhibites the activity of 
Ras, leading to decreased proliferation and migration of RL95-2 cells49. Overexpression of 
estrogen receptor β (ERβ) inhibits proliferation and invasion of tumor cells in breast cancer 
and endometrium50,51. 
2.4 Ovarian cancer 
Ovarian cancer ranks the fifth as a cause of neoplastic death among women worldwide30. 
There would be around 22,440 new cases and 14,080 deaths in the United States in 201731. 
Incidence rates are highest in more developed regions, with rates of more than 7.5 per 
100,00030. The overall 5-year survival rate of ovarian cancer is just approximately 30-40%52. 
The fundamental problem in treating ovarian cancer is that it is not easy to discover it at an 
early stage and accomplish complete curative resection. Ovarian cancer histological groups 
include type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-
epithelial and non-specific tumors53. Among all the subtypes, type II epithelial tumors are 
the most common in Oceania, North America and Europe, while type I epithelial tumors are 
more common in Asia during 2005-200953. Type II epithelial tumors are associated with 
poorer survival than type I epithelial, germ cell and sex cord-stromal tumors53.  
2.4.1 COX and ovarian cancer 
COX-2-/- female mice show defective ovulation, fertilization and implantation54. The mRNA 
expressions of COX-1, COX-2, EP2 and EP4 are detected in both granulosa and cumulus cells 
in mice periovulatory follicles during superovulation55. COX-1, COX-2, mPGES-1, EP1 and EP2 
are expressed predominantly in epithelial cells of human epithelial ovarian cancer56. Kino et 
al. (2005) believed that COX-1 is the primary enzyme for producing PGE2 instead of COX-2 in 
ovarian cancer cells. Because the elevated expression of COX-1 instead of COX-2 was 
detected in 22 ovarian cancer tissues compared with that in normal cases57, and SC-560 (a 
COX-1 inhibitor) can suppress the production of PGE2 in three ovarian cancer cell lines while 
NS-398 and rofecoxib (COX-2 inhibitors) can not57.  However, the latest meta-analysis (2017) 
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suggested that COX-2 expression is correlated with FIGO stage, histological type and patients’ 
age and the high expression of COX-2 is associated with reduced OS and DFS of ovarian 
cancer patients58. In addition, high expression of COX-2 is associated with a shorter 
progression time and overall survival time in the patients who firstly underwent explorative 
laparotomy and then received chemotherapy59. It implies that COX-2 is also correlated with 
chemotherapy resistance.  
    For in vitro studies, COX-2 can stimulate the proliferation, migration, apoptosis and 
angiogenesis of ovarian cancer cells. COX-2 enhances proliferation and migration of human 
ovarian cancer CAOV-3 cells mainly through activation of phosphatidylinositol 3-
kinase/protein kinase B (PI3-k/Akt) pathway60. By analyzing the epithelial ovarian cancer 
(EOC) tissues and EOC cell lines (MDAH2274 and SKOV3), Uddin and his colleagues 
demonstrated that COX-2 modulates cell growth and apoptosis also through PI3K/AKT 
signaling pathway in EOC61. Furthermore, Uddin et al. proved that COX-2 could be a potential 
therapeutic target in EOC because treatment of xenografts together with aspirin can inhibit 
tumor growth in nude mice through decreasing the expression of COX-2 and Akt61. COX-2 
protein levels correlate with VEGF protein levels and microvessel counts in ovarian 
carcinoma62.  
    The expression of COX-2 is regulated by various cytokines in ovarian cancer cells, such EGF, 
vitamin D, IL-1β. EGF induces the production of both COX-2 and PGE2 via the activation of 
the PI3K/Akt signaling pathway, resulting in an invasion of SKOV3 and OVCAR5 cells (two 
human ovarian cancer cell lines)63. A reduced level of vitamin D receptor (VDR) and an 
induced level of COX-2, 15-PGDH and PGE2 are found in the serum of ovarian cancer patients 
older than 45 years64, suggesting an interaction between PG and vitamin D-metabolism in 
ovarian cancer. The mRNA and protein expression of COX-2 can be stimulated by IL-1β and 
phorbol ester (TPA) in OVCAR-3 cells and by TPA in CAOV-3 cells65. 
2.4.2 EPs and ovarian cancer 
PGE2 can induce cell invasiveness via the increasing the expression of MMP-2 and MMP-9 in 
two human ovarian cancer cell lines (CaOV-3 and SKOV-3)66. PGE2 stimulates the VEGF 
production in HEY ovarian cancer cells mainly via activating EP2 and EP4, which can be 
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reversed by AH23848 (an antagonist of both EP2 and EP4)67. In addition, PGE2-induced EP4 
receptor signaling induces MMP production and ovarian cancer cell invasion through Src-
mediated EGFR transactivation67. EP2 plays a vital role in the process of ovulation and 
fertilization because cumulus expansion becomes decreased in EP2-/- mice68. By feeding hens 
10% flaxseed-enriched or standard diet for four years, Eilati et al. proved a decreased 
expression of COX-2 and PGE2, as well as a reduction in ovarian cancer severity and 
incidence69. 
2.5 Cervical cancer 
Cervical cancer is the fourth most common cancer and the fourth most common cause of 
cancer-related death among women worldwide70. The incidence and prevalence of cervical 
cancer are higher in the developing countries than in the developed countries owing to a 
lack of screening, availability of vaccine, and awareness of HPV infections71. In the United 
States in 2017, there were an estimated 12,820 cases and 4,210 deaths from cervical 
cancer31. In many developing countries, cervical cancer causes more than one-quarter of a 
million deaths per year72. The 5-year survival rate of cervical cancer is between 63-79% in 
China, Singapore, South Korea and Turkey, less than 25% in Gambia and Uganda73. The two 
main malignant epithelial cervical cancer types are the squamous cell carcinoma and the 
adenocarcinoma74.  
The human papillomavirus (HPV) infection is the crucial risk factor for cervical cancer75, 
and inflammation after the HPV infection is a driving force that increases cancer 
development76. HPV is present in more than 90 % of squamous cell cervical cancer cases 
worldwide and in nearly 90% of adenocarcinomas of women younger than 40 years old 77. 
HPV serotype 16, 18, 45, 31, 33, 52, 58 and 35 are the most common serotype of HPV in 
women with cervical cancer72. High-risk HPV 16 encodes three oncoproteins: E5, E6 and E778. 
E5 proteins induce COX-2 expression, and COX-2 increases PGE2 secretion and EP4 
expression79. E6 proteins can inactivate p53, block cell apoptosis, disrupt cell adhesion, alter 
transcription and reduce immune recognition80. E7 proteins inactivate pRb to force the host 
cell to keep cell division and induce genomic instability81. 
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2.5.1 COX-2 and Cervical cancer  
High expressions of COX-2 and PGE2 have been found in the cervical carcinoma82,83. COX-2 is 
overexpressed in various types of cervical neoplasm such as cervical intraepithelial neoplasia 
(CIN), adenocarcinoma and squamous cell carcinoma, implying that COX-2 expression is 
highly associated with cervical carcinoma development and progression10. Many studies 
show that COX-2 contributes to carcinogenesis and progression of cervical cancer. High 
expression of COX-2 is related to poor overall survival (OS) and poor disease-free survival 
(DFS) in cervical cancer patients84. COX-2 is also associated with poor DFS in chemo-radiation 
subgroup, implying COX-2 is a chemo-radiation resistance predictive factor for cervical 
cancer84. The COX-2 expression is more frequently expressed in adenocarcinoma than in 
squamous cell carcinoma by immunohistochemistry85. The co-expression of COX-2 and 
thymidine phosphorylase (TP) is related to poor 5-year disease-free and overall survival 
rates, suggesting that the combination of COX-2 and TP is a prognosticator for squamous cell 
carcinoma of the cervical cancer86. 
    The expression of mPGES-1 is higher in squamous intraepithelial lesions and carcinoma of 
the uterine cervix compared with the normal cervical epithelium87. Radilova et al. (2009) 
found that COX-1 is also coupled with mPGES-1 for co-regulating PGE2 synthesis in human 
cervix cancer cells88. Dimethylcelecoxib (a non-COX-2 inhibitor) inhibits the early growth 
response protein 1 (EGR1) and transcription of mGPES-1 via an enhanced complex of NF-κB 
and histone deacetylase 1 (HDAC1) that binds to the EGR1 promoter in Hela cells89.  
2.5.2 EPs and Cervical cancer 
Sales et al. (2001) reported that the syntheses of COX-2, PGE2, EP2, EP4 and cyclic adenosine 
monophosphate (cAMP) are up-regulated in cervical cancer tissue compared to that in the 
healthy cervix, suggesting that PGE2 may regulate neoplastic cell function via the EP2/EP4 
receptors82. Sales and his colleagues further in 2002 proved that PGE2 could induce the 
expression of COX-2, EP4 and cAMP in Hela cells which were transiently transfected with EP2 
or EP4 cDNA83. However, this research did not detect whether the expression of cAMP 
would be decreased after knocking out or knocking down the expression of EP2 or EP4. Kurt 
J. et al. (2002) observed that rapid accumulation of cAMP is produced in Hela cells after 
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being stimulated with PGE2, which is mediated via the cAMP-linked EP2/EP4 receptors83. 
Both studies imply that PGE2 regulates the function of cervical cancer cells mainly via cAMP-
linked EP2/EP4 signaling pathway.  
    Jung-Min et al. (2009) showed an increased expression of EP4 in 52 cervical cancer tissues 
compared with four healthy controls by immunohistochemistry79. This study also 
demonstrated that HPV16 E5 upregulated the activity of PGE2-EP4-cAMP signaling pathways 
by inducing the binding of cyclic adenosine monophosphate response element binding 
protein (CREB) to a variant CRE site in the promoter of the human EP4 gene79. EP4 plays a 
role in the proliferation and angiogenesis of cervical cancer cells since GW627368X (a highly 
selective EP4 antagonist) inhibits the proliferation and angiogenesis of cervical carcinoma by 
blocking EP4/EGFR signaling pathway in cervical cancer cell lines (HeLa, SiHa and ME 180) 
and suppresses the tumor size in xenograft mice model90.  
    It has recently demonstrated that overexpression of EP3 in cervical cancer patients is 
associated with impaired prognosis in overall survival rates when evaluating 250 cervical 
cancer patients with immunohistochemistry91. As an independent prognosticator for cervical 
carcinoma, the EP3 receptor is also significantly correlated with lymph node stage and FIGO 
stage91. However, the pathological mechanism of how EP3 signaling regulates in cervical 
cancer is still unclear. 
2.6 Recurrent miscarriages 
Trophoblasts and malignant tumors use the same biochemical mediators to degrade 
extracellular matrix degradation and suppress immune reaction of environmental 
conditions92. Recurrent miscarriages (RM) are defined as two or more consecutive failed 
pregnancies before the 20th week of pregnancy according to the Practice Committee of the 
American Society for Reproductive Medicine93. RM is also called recurrent pregnancy losses 
(RPL) affecting 1% of all women worldwide94, and only a small part of reasons can be 
attributed by particular causative factors, comprising genetic abnormalities, structural 
abnormalities, infection, endocrine abnormalities, immune dysfunction and thrombophilic 
disorders93. Up to 50% of RM cases are classified as unexplained RM (uRM).  
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    Inflammation is essential for successful blastocyst implantation, pregnancy maintenance 
and delivery, however, ultimately inflammatory over-reaction has a devastating effect on 
pregnancy outcome, including RM95. Laird et al. (2003) postulated that three mechanisms 
that result in RM: increased activity of uterine natural killer (uNK) cells or macrophages, 
various effects of cytokines on trophoblast and thrombotic effects of cytokines on 
vasculature96. Decreased expression of IL-1β and IL-6 mRNA has been detected in the 
endometrium of RM patients than healthy controls during the mid-sectory phase97. Elevated 
production of Th1 cytokines (interferon-γ, IL-2, IL-12, TNF-β) and downregulated levels of 
Th2 cytokines (IL-6) are found in RM women compared with controls by qualitative reverse 
transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay 
(ELISA)98. Abnormal inflammation in the fetal-maternal interface and unbalanced 
extracellular matrix (ECM) remodeling are also considered as key factors resulting in RM99. 
2.6.1 COX-2-PGE2 and Recurrent miscarriages 
COX-2 is expressed in human endometrial stroma cells100 and it has influence in the 
blastocysts implantation in the early pregnancy phase 101. So far, a limited amount of 
literature exists concerning COX-2 expression levels in RM with conflicting results. Wang et al. 
(2010) reported that lower mRNA and protein expressions of COX-2 have been found in the 
chorionic villi of women with unexplained RM101, and Hua et al. (2013) showed the similar 
result in the mice embryo with autoimmune-type recurrent miscarriages102. Singh et al. 
(2017) reported that increased mRNA levels of MMP-2/MMP-9 were found in 135 C. 
trachomatis-positive RM patients than 120 age-matched controls, and MMP-2 positivley 
correlated with COX-2103. It implies that COX-2 might participate in both inflammatory 
reactions and endometrial matrix degradation in C. trachomatis-positive RM patients. 
    Banerjee et al. (2012) reported that expressions of PGE2 and pro-inflammatory cytokines 
are also induced in the endometrium of women with unexplained RM, such as interleukin 1β 
(IL-1β), tumor necrosis factor α (TNF-α), interferon γ (IFN-γ), and transforming growth factor 
β1 (TGF-β1) 104. IL-1, TNF-α and IFN-γ belong to Th1 cytokines, and this Th1 predominance 
has been known to be one of the immunological reasons for RM105. Additionally, TNF-α can 
induce COX-2 gene expression in first-trimester trophoblasts106. PGE2 is the major 
prostaglandin produced by the placenta107; it can modulate the Th1 and Th2 cell balance 
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responses108, regulate chemokine productions108 and inhibit lymphocyte alloreactivity during 
early pregnancy109. PGE2 is found to be increased in cervical ovulatory mucus110 and the 
endometrium104,111 of RM women compared to healthy controls during implantation. Until 
now there is rare report on the EP receptors expression in the pathological mechanism of 
RM.  
2.7 Drug targeting of COX-2-PGE2-EPs signaling 
Chemoprevention has long been recognized as an important prophylactic strategy to reduce 
the burden of cancer on health care system. Also, nonsteroidal anti-inflammatory drugs 
(NSAIDs) as chemoprevention chemicals have been proved to reduce the risk of several 
cancers in human, such as gastrointestinal cancer, breast cancer, prostate cancer, lung 
cancer and skin cancer112. Nan et al. (2015) found that regular use of aspirin or NSAIDs is 
linked to lower risk of colorectal cancer compared with no regular use after analyzing 8634 
colorectal cancer cases and 8553 matched controls between 1976 and 2011113. Long-term 
use of COX inhibitors in humans leads to a 50% decrease in risk for colorectal cancer25. A 
meta-analysis by Banndrup et al. (2013) suggested the risk of invasive ovarian cancer is 
significantly reduced with the use of aspirin114. 
    NSAIDs include aspirin, ibuprofen and naproxen, and act by inhibiting both COX-1 and 
COX-2. These unspecific inhibitors cause many adverse effects, such as gastrointestinal 
ulcers and bleeds, heart attack and kidney disease115. Selective COX-2 inhibitors (COXibs) has 
been successfully documented and showed less toxicity to gastrointestinal tract as compared 
to traditional NSAIDs116. However, the long-term use of COX-2 selective inhibitors still has 
other side effects. The adverse effects of COX-2 selective and non-selective inhibitors are 
summarized in the latest review by Rayar et al. (2017) including myocardial infarction, 
hypertension, stroke, reduced glomerular filtration rate and renal plasma flow, acute renal 
failure, acute interstitial nephritis, inhibition of ulcer healing, hepatic complications, allergy, 
fatal skin reaction, depression, delayed follicular rupture and so on117. Therefore, further 
exploration of novel anti-inflammation targets is needed. 
    Clinical studies show elevated levels of mPGES-1 are identified in colon, lung, stomach, 
pancreas, cervix, prostate, papillary thyroid carcinoma, head and neck squmaous carcinoma 
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and brain tumors, suggesting mPGES-1 inhibitors might be a potential chemopreventive 
agent16. However, a limited number of compounds that inhibiting mPGES-1 has not been 
successfully developed as anti-cancer agents, such as celecoxib, MF-63, NS-398, MK-866 and 
triclosan16. 
    In recent years, extensive efforts have been made into elucidating the function of PGE2 
and the EP receptors in health and carcinogenesis with the aim of exploring promising 
targets and selective inhibitors as a novel therapy. Many researchers have found the strong 
correlation of EP2/EP4 receptors with colon cancer, skin cancer, mucosa cancer of the 
pharynx and the esophagus, prostate cancer, urothelial cancer and non-small cell lung 
cancer18. The EP4 promotes migration, invasion, angiogenesis and lymphangiogenesis of 
mammary tumor cells118. EP4 receptor is responsible for the PGE2-induced colorectal tumor 
cell proliferation and morphogenic changes via PI3k/Akt signaling pathway119. Mice are not 
able to have inflammatory responses to PGE2, IL-1β or lipopolysaccharide when lacking the 
EP3 receptor, but not EP1, EP2 or EP4 receptor120. Deletion or inhibition of EP3 receptors 
could ameliorate the neuronal apoptosis in the ischemic cortex in EP3 knock-out mice or EP3 
antagonist-treated mice compared with wild-type mice or vehicle-treated mice, respectively. 
It suggests that EP3 is involved in the inflammatory and apoptotic reactions during stroke 
injury121. The investigations concerning EP receptors in gynecological cancers highlight the 
potential advantage of combining COX enzyme inhibitors with EP receptor antagonists as 
therapeutic agents in gynecological cancers.  
    Wang et al. proposed the possible PGE2 downstream targets that might also serve as 
promising specific chemopreventive agents for cancer prevention and treatment, which 
include angiogenic factors (VEGF, bFGF), anti-apoptotic factors (Bcal-2), chemokines (MIP-1α, 
MIP-1β, RANTES, CXCR4) and their receptors, and immunosuppressive mediators7. 
2.8 EP3 and PAI-1 transcription  
It is interesting to notice that EP3 can induce PAI-1 expression, which is also a prognosticator 
in carcinogenesis of numerous cancers. In the development of aortic stenosis, PGE2 utilizes 
EP1/EP3 receptor to increase levels of plasminogen activator inhibitor type 1 (PAI-1) in 
cardiac fibroblasts resulting in elevated fibrin deposition122. PAI-1 is the prime inhibitor of 
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the fibrinolytic system, and its expression affects cell survival, migration and matrix 
remodeling in tumor cells as well as trophoblast cells. PAI-1 can inhibit trophoblasts 
invasion123 while promoting tumor cell immigration. PAI-1 is a biomarker for malignancies 
with poor prognosis because it facilitates many tumor cell migration and invasion123. PAI-1 is 
a poor prognostic factor for early-stage endometrial cancer and advanced stage epithelial 
ovarian cancer patients124,125. Hazelbag et al. (2004) suggested that PAI-1 is also a negative 
prognosticator for the overall and disease-free survival of cervical cancer patients by 
analyzing 108 paraffin-embedded cervical carcinoma tissues126. PAI-1/uPA/uPA receptor 
(uPAR)/low density lipoprotein receptor-related protein (LRP)/integrin complexes are 
initiating an “adhesion–detachment–re-adhesion” cycle to promote tumor cell 
migration123,127. 
    Most pieces of literature illustrate the gene transcription of PAI-1 is regulated by TNF-β, 
and the main signaling pathway includes MEK/ERK and Smad (Figure 2). Hua et al. (1998) 
proved that TGF-β signals through type I and type II receptor serine/ threonine kinases and 
induces PAI-1 gene transcription via Smad3, Smad 4 and transcription factor μE3 (TFE3)128. 
Winkins-Port and his colleagues (2007) suggested that in human cutaneous squamous cell 
carcinoma, TGF-β1 can trans-activate both MEK and EGFR, and then phosphorylate the 
downstream-activated MAP kinases consisting of ERK1/2 and p38129. Thereby TGF-β1 
regulates the PAI-1 gene transcription with members of the Smad family and USF family in 
the nucleus129. Samarakoon et al. (2008) showed two distinct signaling pathways that TGF- β 
initiates PAI-1 transcription in vascular smooth muscle cells, which consist of the 
EGFR/pp60c-src/MEK-ERK pathway and Rho/ROCK-dependent SMAD2 activation130. Freytag 
et al. (2009) demonstrated that Smad 2/3 cooperates with p53 and upstream stimulatory 
factor proteins 1/2 (USF1/2) for maximal TGF-β directed PAI-1 transcription in human 
cutaneous squamous cell carcinoma131. Samarokoon et al. elucidated the extensive cross-
talk among Smad2/3, EGFR, reactive oxygen species (ROS) and tumor suppressor p53 
pathways are necessary for TGF-β1 inducing PAI-1 in renal fibrosis132. ROS production by 
TGF-β1 stimulation is crucial for activation of EGFR and p53, which cooperates with Smad3 
to regulate PAI-1 transcription132. 
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Numerous studies show that significant crosstalk exists between the EP receptors (EP1133, 
EP244 and EP4134) and the EGFR signaling pathway. The EGFR signaling pathway can also 
activate several other signal transduction cascades, principally the MAPK, PI3K/Akt, signal 
transducers and activators of transcription (STAT) and Phospholipase C (PLC) signaling 
pathway, contributing to the pathogenesis and progression of numerous cancers18. However, 
it remains unknown if PGE2-EPs signaling can work through EGFR signaling pathway to 
regulate PAI-1 gene transcription. 
 
 
 
Figure 2. TGF-β1 induces PAI-1 gene transcription via complex signaling pathways. TGF-β1 can 
directly activate MEK through type I and type II receptor, and phosphorylate the downstream-
activated MAP kinases consisting of ERK1/2, which is the main signaling pathway129. TGF-β1 can also 
transactivate EGFR via ROS or c-src, and both EGFR and c-src motivate MEK/ERK1/2130. TGF-β1 can 
also directly phosphorylate the Smad family including Smad 2, 3 and 4 as well as p53, which can bind 
with transcription factors. The transcription factors for PAI-1 include the Smad family128,131, USF 
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family131, p53 SE131, SBE transcription factor μE3 (TFE3)128 in the nucleus. TGF-β1 can also activate Ras 
and Rho/ROCK. The EP receptor signaling pathways also have crosstalk with the EGFR signaling 
pathway18, which can activate several other signal transduction cascades, principally the MAPK, 
PI3K/Akt, STAT and PLC signaling pathways. It remains to be explored if PGE2-EPs signaling can work 
through EGFR signaling pathway to regulate PAI-1 gene transcription. Abbreviation: TGF-β1, 
transforming growth factor β 1; PAI-1, plasminogen activator inhibitor type1; ERK, extracellular 
signal-regulated kinase; ROS, reactive oxygen species; ROCK, Rho-associated coiled-coil kinase; USF, 
upstream stimulatory factor proteins; TFE3, transcription factor μE3; MAPK, Mitogen-activated 
protein kinase cascade; PI3K/Akt, phosphatidylinositol 3-kinase/protein kinase B; STAT, signal 
transducers and activators of transcription; PLC, Phospholipase C. 
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2.9 Aim of the studies 
The pathology underlying gynecological cancer development and recurrent miscarriages is 
not fully understood yet and an inflammatory over-action is one factor, which might play a 
role in the development of gynecological malignancies. COX-2-PGE2-EPs signaling is the main 
pathway involved in inflammation, playing a role in carcinogenesis and miscarriages. A large 
number of studies have demonstrated the effects of COX-2 in gynecological cancer and 
proved high expression of COX-2 and PGE2 benefits tumor development. Furthermore, 
NSAIDs or specific COX-2 inhibitors can successfully suppress tumor growth and 
inflammatory reaction. However, the side effects of NSAIDs or specific COX-2 inhibitor 
(COXibs) have also raised people’s attention, including the gastrointestinal ulcers and bleeds, 
cardiology effects and stroke. Therefore, it is urgent to explore more effective and specific 
targets for cancer and RM therapy. 
    Limited information is available about the potential role for EPs in gynecological cancer as 
well as in recurrent miscarriages. Most of the studies have explored EP2/EP4 expression in 
the mechanism of cervical cancer and endometrial cancer. The effects of EP3 are still unclear 
on the cervical cancer, as well as on RM. We aimed to explore the EP3 signaling in the 
mechanism of cervical cancer and recurrent miscarriages from the perspective of 
inflammation. Therefore, this thesis is divided into two parts: 1) EP3 signaling in the 
carcinogenesis of cervical cancer; 2) EP3 signaling in the pathological mechanism of 
recurrent miscarriages. In addition, the possible correlation between EP3 signaling and 
plasminogen activating system during cancer development and miscarriages has been 
investigated. Based on the in vivo and in vitro studies, the intention was to explore the 
potential effects of EP3 antagonist (L-798,106) as a therapeutic approach to treat cervical 
cancer and recurrent miscarriages. 
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3. Material and methods  
3.1 Cell culture and stimulation 
CaSki cells (CRL-1550) and Hela cells (CCL-2) were used as cervical cancer cell models, while 
JEG-3 cells (ATCC HTB-36, Manassas, USA) and HTR-8/SVneo cells (ATCC CRL-3271, 
Manassas, USA) were used as trophoblast models. All of them were obtained from the 
American Type Culture Collection (ATCC). All cell lines were cultured in RPMI 1640 medium + 
Gluta MAXTM (Gibco, USA) supplemented with 10% fetal bovine serum (FCS, Gibco, USA) 
without antibiotics or antimycotics. Cells were cultured in 96-well plates for the cell 
proliferation assay, 24-well plates for the wound healing assay and the enzyme-linked 
immunosorbent assay (ELISA) test, and 6-well plates for western blotting. After 6-8 hours, 
cell culture medium was replaced with fresh RPMI1640 with stimulation chemicals for the 
remaining 48 hours, which included dimethyl sulfoxide (DMSO, 0.5%) as vehicle control, 
PGE2 (TOCRIS, USA), sulprostone (TOCRIS, USA) and L-798,106 (TOCRIS, USA). 
3.2 Cell proliferation and viability assay 
Both CaSki and Hela cells were cultured at a density of 1.5 × 104 cells/well in 96-well plates 
and were incubated with different concentrations (1, 10 and 100 nM) of sulprostone 
(TOCRIS, USA) for 24 h, 48 h and 72 h. JEG-3 cells were seeded at the density of 1.5 × 104 
cells/well in 96-well plates and were incubated with different concentration of PGE2 and L-
798,106 for 48 h. The dimethyl sulfoxide (DMSO, 0.5%) always served as a vehicle control. 
    Cell proliferation was analyzed with a 5-bromo-2’-deoxy-uridine (BrdU) labeling and 
detection kit (Roche Diagnostics GmbH, Mannheim, Germany) according to the 
manufacturer’s instructions. Cells were incubated with BrdU (20 µl/well) for 24 h, and then 
fixed with fixing solution for 30 min. After adding anti-BrdU-POD working solution (100 
µl/well), BrdU incorporation into the cellular DNA was measured by an ELISA technique. The 
optical density (OD) was examined at 450 nm using Elx800 universal Microplate Reader. At 
least six replicates were performed with each cell line. 
    Cell viability assay was performed in JEG-3 cells, 20 μg MTT [3-(4,5-dimethhylthiaoly)-2,5-
diphenyltetrazolium bromide] (Sigma) was added to each well for 1.5 h at 37 °C. After 
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removing MTT, 200 μl DMSO was added to each well and mixed thoroughly on the shaker 
for 5 min at room temperature. The optical density (OD) was examined at 595 nm using 
Elx800 universal Microplate Reader. 
3.3 Wound Healing (Scratch) Assay 
2.5 × 105/well of CaSki cells and 1.2 × 105/well of Hela cells were cultured in 24-well plates 
for two days. On the third morning the central fields of confluent monolayers were 
scratched with 200 µl pipette tips to make artificial wound gaps. Then each well was rinsed 
with phosphate-buffered saline (PBS) to remove the detached cells. Fresh RPMI1640 with 
DMSO (0.5%) and 100 nM sulprostone was added respectively. Cell migration was monitored 
by photographing with an inverse phase contrast microscope (Leica Dmi1, Leica, Wetzlar, 
Germany) for 0 h and 24 h. Photos of cells migration area were analyzed with software 
Image J (https://imagej.nih.gov/ij/). The cell migration area = area at 0 h – area at 24 h. 
3.4 Western Blotting 
Cell lysates were extracted from CaSki, Hela, JEG-3 and HTR-8/SVneo cells with 
radioimmunoprecipitation assay buffer (RIPA, Sigma-Aldrich, R0278-50ML). 20µg of cell 
lysates for western blotting were first separated in 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and then transferred to a polyvinylidene fluoride 
membrane (Bio-Rad, USA). The membrane was blocked in 4% skim milk powder and then 
incubated with the primary antibodies for 16 hours at room temperature. Different primary 
antibodies were used as follows: rabbit polyclonal anti-EP3 antibody (Abcam, ab94496, 
1:500), goat polyclonal anti-EP1 antibody (MyBioSource, MBS420141, 1:150), rabbit 
polyclonal anti-Gi1 antibody (Novus Biologicals, NBP2-16558, 1:500), rabbit polyclonal anti-p-
ERK1/2 antibody (Abcam, ab47339, 1:500), rabbit polyclonal anti-uPAR antibody (Abcam, 
ab218106, 1:300), mouse monoclonal anti-p53 antibody (Abcam, ab26, 1:200). Β-actin was 
used as a housekeeping gene and mouse monoclonal anti-β-actin antibody was diluted as 
1:1000 in 4% milk powder (Sigma, A5441). Afterwards, the membrane was incubated with 
the goat-anti-rabbit/-mouse secondary antibody conjugated with alkaline phosphatase 
(1:1000 dilution, Jackson Immuno Research, UK), and detected with 5-bromo-4-chloro-3’-
indolylphosphate/nitro-blue tetrazolium (BCIP/NBT) -chromogen substrate solution 
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(Promega). Western blots were scanned and quantified using the GelScan V6.0 1D Analysis 
Software (SERVA, Electrophoresis GmbH, Heidelberg, Germany). Band intensities of EP3, 
EP1, Gi1, p-ERK1/2 and uPAR were normalized with band intensities of β-actin. The blots 
were repeated at least three times.  
3.5 ELISA  
3.5.1 PAI-1 and uPA  
Both CaSki and Hela cells were cultured at a density of 5 × 104 cells/well in 24-well plates and 
were incubated with 10 nM of PGE2, sulprostone and L-798,106, respectively. After 48 hours, 
the supernatants of both cell lines were harvested. The levels of PAI-1 in the supernatants of 
Hela and CaSki cells were measured utilizing a commercially available enzyme-linked 
immunosorbent assay (ELISA) kit (R&D system, DSE100, Minneapolis, MN, USA). A standard 
curve of PAI-1 was obtained for each assay and results were converted into ng/ml. The intra- 
and inter-assay variability of PAI-1 was 4.6% and 8.7%, respectively. The levels of uPA in the 
supernatants of both cell lines were also evaluated using a commercially available ELISA kit 
(R&D system, DPUA00, Minneapolis, MN, USA). A standard curve of uPA was obtained for 
each assay and results were converted into pg/ml. The intra- and inter-assay variability of 
uPA was 2.1% and 7.1%, respectively. 
3.5.2 β-hCG and progesterone 
Both JEG-3 (50’000 cells/ well) and HTR-8/SVneo cells (60’000 cells/ well) were incubated 
with PGE2, sulprostone and L-798,106 at different concentrations of 0.1, 1, 10, 100, 1000 nM 
and 10 µM in 24- well plates for 48 hours. Supernatants of JEG-3 and HTR-8/SVneo cells in 
24-well plates were collected and centrifuged (13200g, 10min) to remove debris. The 
concentration of β-hCG and progesterone in the supernatant was detected according to the 
manufacturer’s instructions on an ADVIA Centaur XP auto 23nalyser (Siemens Medical 
Solution Diagnostics) as described in our previous publications (32, 33). The concentration of 
total β-hCG was measured in a two-site sandwich immunoassay (ADVIA Centaur Total hCG 
Test; Siemens Medical Solutions Diagnostics). The detectable concentration of total β-hCG 
ranges from 2.0 mIU/ml to 1000 mIU/ml. The concentration of progesterone in supernatants 
was measured by an automated quantitative immunoassay (ADVIA Centaur Progesterone 
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Test; Siemens Medical Solutions Diagnostics) with a sensitivity of 0.2ng/ml. Intraobserver 
and interobserver coefficients of variation were 9.8% and 5.8%, respectively. 
3.6 Clinical samples 
3.6.1 cervical cancer tissues 
We analyzed paraffin-embedded cervical cancer samples from 250 patients having 
undergone surgery for cervical cancer in the Department of Obstetrics and Gynecology in the 
Ludwig-Maximilians-University of Munich, Germany between 1993 and 2002. This study was 
approved by the ethical committee of the Medical Faculty, Ludwig-Maximilian-University of 
Munich (approval number: 259-16). The informed consent was obtained from each patient 
and all methods were performed in accordance with the relevant guidelines and regulations. 
Staging and grading were assessed by two gynecological pathologists according to the 
criteria of FIGO and WHO. Follow-up data were received from the Munich Cancer Registry 
(Munich Tumor Center, Munich, Germany). Samples and clinical information were 
anonymized and encoded for statistical workup. All clinical information was blinded from the 
authors during experimental analysis. 
    Detailed clinic characteristics of 250 cervical cancer patients are listed in Table 1, which 
includes age, follow-up months, stage, grading, histology and survival months. The outcome 
was assessed by patients’ overall survival (OS). OS is defined as the time from diagnosis to 
the death or to the date of the last follow-up. 76% (190/250) of the cohort survived over 235 
months and 19.6% (49/250) of the cohort died. The information of the rest 4.4% (11/250) of 
the cervical cancer patients is missing. 
3.6.2 Placental tissue samples 
We analyzed placenta tissues of 19 patients with a history of more than two consecutive 
pregnancy losses of unknown causes (uRM group) and of 19 healthy controls with legal 
pregnancy termination (control group) from a private practice in Munich, Germany. 
Exclusion criteria for the uRM group, described thoroughly in our previous studies135, include 
infectious diseases, uterine anomalies, endocrinological dysfunctions, hyperprolactinemia, 
hyperandrogenemia, thyroidal dysfunctions, autoimmunologic disorders, deficiencies in 
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coagulation factors, as well as fetal and parental chromosomal disorders. All placentas were 
obtained within the first 24 hours after diagnosis without any prior hormonal pretreatment. 
Samples were obtained by dilatation and evacuation without any prior pharmaceutical 
induction. These samples were fixed immediately in 4% buffered formalin for 20-24 hours 
and embedded in paraffin for further immunohistochemical and double 
immunofluorescence analysis. The study was approved by the ethical committee of the 
Medical Faculty, Ludwig-Maximilian-University of Munich (Number of approval: 337-06) and 
informed consent was obtained from each patient in written form. Samples and clinical 
information were anonymized and encoded for statistical workup. 
3.7 Immunohistochemistry 
Paraffin-embedded slides (3µm-thick) were dewaxed in xylol and washed in 100% ethanol. 
For inhibition of the endogenous peroxidases, tissue samples were incubated in methanol 
with 3% H2O2 and rehydrated in a descending alcohol series. Slides were heated in a 
pressure cooker using sodium citrate buffer (pH=6.0), containing 0.1 M citric acid and 0.1 M 
sodium citrate in distilled water. After cooling and washing in phosphate-buffered saline 
(PBS), all slides were incubated with a blocking solution (Reagent 1, Zytochem-Plus HRP-
Polymer-Kit (mouse/rabbit)) for 30 min to avoid non-specific binding of the primary 
antibodies. The slides from cervical cancer patients were incubated with rabbit polyclonal 
anti-uPAR antibody (Abcam, ab218106, 1:300 dilution) for 16 hours at 4°C. The primary 
antibodies used for recurrent miscarriages patients were anti-COX rabbit IgG polyclonal 
antibody (Sigma, SAB4502491, 1:400 dilution), anti-EP3 rabbit IgG polyclonal antibody 
(Abcam, ab189131, 1:300 dilution) and anti-Gi1 rabbit IgG polyclonal antibody (Novus 
Biologicals, NBP2-16558, 1:1000 dilution). After washing, the secondary 
antibodies/complexes of HRP-polymer (Zytochem-Plus HRP Polymer-kit, Zytomed, Berlin, 
Germany) were applied following the manufacturer’s protocols to detect reactivity. uPAR 
immunostaining was visualized with the substrate and the chromogen-3, 3’-
diaminobenzidine (DAB; Dako, Hamburg, Germany) after 3 min, 1 min for COX-2, 2.5 min for 
EP3 and 45 sec for Gi1.      
    Metastatic colon carcinoma was used as a positive and negative control for the 
immunohistochemical staining of uPAR to test antibody function and to determine an 
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appropriate dilution of the antibody for staining.  Colon was used as a positive control for 
EP3 while Third-trimester placenta was used as a positive control for the 
immunohistochemical staining of COX-2 and Gi1. Positive cells showed a brownish color and 
the negative control, as well as unstained cells, appeared blue43. Negative controls were 
conducted with the same control tissues and were performed by replacement of a pre-
immune serum (Negative Control for Super Sensitive Rabbit Antibodies, BioGenex, 
California, USA) at the same concentration as the anti-uPAR antibody. 
    All slides were analyzed under the microscope by two independent observers using a Leitz 
(Wetzlar, Germany) photomicroscope. For the light microscopy analysis, a semi-quantitative 
IRS score was used44, which was calculated via the multiplication of optical staining intensity 
(grades: 0=no, 1=weak, 2=moderate and 3=strong staining) and the percentage range of 
positive stained cells (0=no staining, 1= ≤10% of the cells; 2=11-50% of the cells; 3=51-80% of 
the cells and 4= ≥81% of the cells were stained with the anti-uPAR antibody, respectively). 
3.8 Double Immunofluorescence staining 
For the characterization of COX-2, EP3 and Gi1-expressing cells in the decidua, we applied the 
same paraffin-embedded slides with double immunofluorescence staining. The same 
experimental steps were carried out as for immunohistochemistry until the step of blocking. 
Slides were blocked with a blocking solution (Ultra V Block, Lab Vision, Fremont, CA, USA) to 
avoid non-specific staining and then incubated with various primary antibodies overnight at 
4°C. Prolactin was used as a specific marker for stromal cells and HLA-G was used as a 
specific marker for trophoblast cells. Different primary antibodies were diluted with a 
diluting medium (Dako, Hamburg, Germany) according to the following ratios: 1:400 for 
rabbit anti-COX-2 polyclonal IgG (Sigma, SAB4502491) and 1:500 for mouse anti-Prolactin 
polyclonal IgG (Serotec, MCA712), 1:300 for rabbit anti-EP3 polyclonal IgG (Abcam, 
ab189131), 1: 300 for rabbit anti-Gi1 polyclonal IgG (Novus Biologicals, NBP2-16558), 1:50 for 
mouse anti-HLA-G polyclonal IgG (Serotec, MCA2044). After washing, slides were incubated 
with Cy2-/Cy3-labeled antibodies (Jackson Dianova, Hamburg, Germany) as fluorescent 
secondary antibodies for 30 min at room temperature in darkness to avoid fluorescence 
quenching. Cy2-labeled secondary antibodies were at a dilution of 1:100 and Cy3-labelled 
antibodies were at a dilution of 1:500. Finally, the slides were embedded in mounting buffer 
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containing 4’,6-diamino-2-phenylindole (DAPI, Vectastain, Vector Laboratories, Burlingame, 
CA, USA) for blue staining of the nucleus after washing and drying. Digital images were 
obtained with a digital camera system (Axiocam; Zeiss CF20DXC; KAPPA Messtechnik, 
Gleichen, Germany) and digitally saved. 
3.9 Statistical analysis 
All data were analyzed with SPSS Statistics 24 software (IBM Corporation, Armonk, NY, USA) 
and are expressed as the mean ± standard deviation (SD). Mann-Whitney-U test was applied 
for evaluating non-parametric variables, such as the proliferation rate and cell migration 
area between the stimulation group and control group. Wilcoxon test was performed for the 
evaluation of PAI-1, uPA, β-hCG and progesterone expression levels and the band intensities 
of EP3, EP1, Gi1, p-ERK1/2 and uPAR between stimulation and control groups. Independent t-
test was used to compare the clinical data. Mann-Whitney-U test was also applied for 
evaluating IRS scores of EP3, COX-2, Gi1 and uPAR expression. Spearman’s rank correlation 
analysis was adopted to evaluate the correlation between two monotonic, nonlinear 
variables. The ROC curve was drawn to identify an appropriate cut-off value which can 
maximize the sum of sensitivity and specificity. Survival time was compared using Kaplan-
Meier (long-rank) test method. We also used a Cox-regression model for multivariate 
analyses. P-values <0.05 were regarded as statistically significant. 
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4 Results 
4.1 EP3 signaling in cervical cancer 
4.1.1 EP3 agonist stimulates the proliferation of CaSki and Hela cells 
In our latest publication, we observed that high expression of EP3 (IRS≥2) is correlated with 
poor prognosis in overall survival rates of cervical cancer patients (P=0.016, Figure 1A)91. In 
the present study, we aimed to investigate the pathological mechanism of how EP3 signaling 
pathway has an effect on the proliferation and migration of cervical cancer cells. Therefore, 
for in vitro investigations, we used CaSki and Hela cells as our models of cervical cancer cells.  
    In vitro, BrdU assay was used to assess the relative proliferation rate of CaSki and Hela 
cells stimulated with different concentrations (1, 10 and 100 nM) of sulprostone. 
Sulprostone (an EP1/EP3 agonist) increased the proliferation rate of CaSki cells in a dose-
dependent manner compared to the control group after 24 hours (each P<0.05, Figure 1B). 
1, 10 and 100 nM sulprostone enhanced the proliferation rate of Hela cells compared to the 
control group after 72 hours (each P<0.05, Figure 1C).  
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Figure 1. EP3 agonist stimulates proliferation of cervical cancer cells. (A) High EP3 expression 
(IRS≥2) is associated with a shorter overall survival (OS) in cervical cancer patients (P=0.016). (B) BrdU 
assay showed the relative proliferation rate of CaSki cells is increased by 1, 10 and 100 nM of 
sulprostone (an EP1/EP3 agonist) in a dose-dependent manner (*P<0.05). (C) BrdU assay showed the 
relative proliferation rate of Hela cells is elevated by 1, 10 and 100 nM of sulprostone (*P<0.05). 
Results are normalized to cell viability of the control group (0.5% (v/v) DMSO). Bar graphs represent 
mean ± SD (n=6).*P<0.05 is considered as significantly different after comparison between the 
stimulation group and the control group. 
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4.1.2 EP3 agonist stimulates the migration of CaSki and Hela cells 
To identify whether EP3 could facilitate the migration of cervical cancer cells, we performed 
wound healing assay. The results showed the relative migration rate was significantly 
enhanced in both CaSki (P=0.046, Figure 2A.2B) and Hela cells (P=0.015, Figure 2C.2D) after 
the treatment of 100 nM sulprostone for 24 hours compared to that in the control group.  
 
Figure 2. EP3 agonist stimulates migration of cervical cancer cells. (A) Representative photographs 
show the migration of CaSki cells into the wounded area in the control group and in the group 
treated with 100 nM sulprostone after 24 hours. (B) Wound healing assay observed the relative 
                                                                                                                                            Results 
31 
 
migration rate of CaSki cells is enhanced in the group treated with 100 nM sulprostone compared to 
the control group (*P<0.05). (C) Representative images show the migration of Hela cells into the 
wounded area in the control group and in the group treated with 100 nM sulprostone after 24 hours. 
(D) Wound healing assay observed the relative migration rate of Hela cells is increased in the group 
treated with 100 nM sulprostone compared to the control group (*P<0.05). Bar graphs represent 
mean ± SD (n=6). *P<0.05 is considered as significantly different after comparison between the 
stimulation group and the control group.  
 
4.1.3 Influence of the EP3 agonist and antagonist on the expression of EP3 
signaling in CaSki and Hela cells 
Western blotting was utilized to assess the expression of EP3 signaling (EP3, Gi1, p-ERK1/2 
and p53) in CaSki and Hela cells stimulated with 100 nM of each PGE2, sulprostone and L-
798,106 for 48 hours (Figure 3A). The molecular weight of EP3 is around 35 kDa. EP3 
expression was decreased by 17.0% in CaSki cells after treatment with 100 nM L-798,106 
compared to the control group (P=0.012, Figure 3B). By contrast, the expression of EP3 was 
not altered by any stimulation substances in Hela cells. EP3 signals are primarily involved in 
inhibition of AC via activating Gi1, whose mass is 40 kDa. The expression of Gi1 was 
downregulated by 14% via 100 nM PGE2 in Hela cells compared to the control (P=0.024, 
Supplementary Figure 1A.1D). The rest of stimulators did not alter the expression of Gi1 in 
either of two cell lines (Supplementary Figure 1A.1D.1E). The molecular weights of p-ERK1/2 
are 44 and 42 kDa. The expression of p-ERK1/2 was decreased by 7.8% through 100 nM L-
798,106 compared to the control group in CaSki cells (P=0.028, Figure 3C) and was increased 
by 47.8% through 100 nM sulprostone compared to the control group in Hela cells (P=0.028, 
Figure 3D). The band signals of p53 in CaSki and Hela cells could not be detected by western 
blotting. 
    Since sulprostone is an agonist for both EP3 and EP1, we also examined the expression of 
EP1 in CaSki and Hela cells by western blotting. The molecular weight of EP1 is around 70 
kDa. There was no significant change in EP1 expression in both CaSki and Hela cells 
stimulated with 100 nM of each PGE2, sulprostone or L-798,106 for 48 hours (each P>0.05, 
Supplementary Figure 1A.1B.1C).  
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Figure 3. Expression of EP3 and p-ERK1/2 in Hela and CaSki cells influenced by PGE2, sulprostone 
and L-798,106. (A) Western blotting analysis shows the expression of EP3 and phosphorylated 
extracellular signal-regulated kinases (p-ERK1/2) in CaSki and Hela cells following treatment with 100 
nM of each PGE2, sulprostone and L-798,106 for 48h. Βeta-actin was used as a loading control and all 
the data was normalized to the β-actin band signals. (B) The histogram illustrates the expression of 
EP3 is inhibited by 100 nM L-798,106 in CaSki cells (*P<0.05). (C) The histogram illustrates the 
expression of p-ERK1/2 is inhibited by 100 nM L-798,106 in CaSki cells (*P<0.05). (D) The histogram 
illustrates the expression of p-ERK1/2 is stimulated by 100 nM sulprostone in Hela cells (*P<0.05). All 
data are shown as mean ± SD (n=3). Full-length blots are shown in Supplementary Figure 3. 
Statistically significant differences (P<0.05) between individual treatment groups and the control 
group are marked with an *.  
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Supplementary Figure 1. The expression of EP1 and Gi1 in Hela and CaSki cells influenced by PGE2, 
EP3 agonist and antagonist. (A) The western blotting analysis of EP1 and Gi1 in CaSki and Hela cells 
following treatment with 100 nM of each PGE2, sulprostone and L-798,106 for 48 h (n=3). (B) 
Histogram illustrates the expression of EP1 in CaSki cells is not altered by PGE2, sulprostone or L-
798,106 (Wilcoxon test). (C) Histogram shows the expression of EP1 in Hela cells is not changed by 
PGE2, sulprostone or L-798,106 (Wilcoxon test). (D) Histogram illustrates the expression of Gi1 is 
inhibited by 10 nM of PGE2 in CaSki cells (*P<0.05, Wilcoxon test). (E) Histogram illustrates the 
expression of Gi1 in Hela cells is not altered by PGE2, sulprostone or L-798,106 (Wilcoxon test). Βeta-
actin was used as a loading control and all the data was normalized to the β-actin band signals. All 
data is shown as mean ± SD. Full-length blots are shown in Supplementary Figure 3. *P<0.05 is 
considered as significantly different after comparison between the stimulation group and the control 
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group. 
 
 
 
Supplementary Figure 3. Full-length blots of EP3, EP1, Gi1, uPAR, p-ERK1/2 and p53. 
 
4.1.4 Influence of the EP3 agonist and antagonist on the expression of PAI-1, 
uPA and uPAR in CaSki and Hela cells  
The plasminogen activating system plays an important role in tumor progression and can be 
affected by EP3 signaling pathway. Therefore, we analyzed the expression of PAI-1 and uPA 
in the supernatants of CaSki and Hela cells stimulated with 10 nM of each PGE2, sulprostone 
and L-798,106 using ELISA. PAI-1 levels in the supernatants of CaSki cells were elevated by 
22.3% through sulprostone and by 25.4% through L-798,106 compared to the control group 
after 48 hours, respectively (both P values<0.001, Figure 4A). The same trend was observed 
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in Hela cells: PAI-1 levels in the supernatants were enhanced by 11.2% via sulprostone 
(P=0.033, Figure 4B) and by 5.7% via L-798,106 (P<0.001, Figure 4B) compared to the control 
group after 48 hours. The levels of uPA in the supernatants of CaSki cells were inhibited by 
5.9% via 10 nM sulprostone (P<0.001, Figure 4C) and stimulated by 5.6% via 10 nM L-
798,106 in CaSki cells (P=0.04, Figure 4C) compared to the control group.  
The expression of uPAR was detected by western blotting and the molecular weight of 
uPAR is between 35-65kDa. In the western blotting, the expression of uPAR in CaSki cells was 
inhibited by 18.4% through L-798,106 compared to the control group (P=0.011, Figure 4D, 
Supplementary Figure 3). Although the expression of uPAR in CaSki cells was stimulated by 
17.5% through sulprostone, there was no significant difference when compared to the 
control group (P=0.26, Figure 4D, Supplementary Figure 3). The expression of uPA and uPAR 
could not be detected in Hela cells.  
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Figure 4. Expression of PAI-1, uPA and uPAR in CaSki and Hela cells influenced by PGE2, sulprostone 
and L-798,106. (A) PAI-1 levels in the supernatants of CaSki cells are elevated after treatment with 10 
nM of each sulprostone and L-798,106 for 48 h by ELISA (*P<0.05, **P<0.001, n=12). (B) PAI-1 levels 
in the supernatants of Hela cells are increased after treatment with 10 nM of each sulprostone and L-
798,106 for 48 h by ELISA (*P<0.05, **P<0.001, n=12). (C) uPA expression levels in the supernatants 
of CaSki cells are inhibited by 10 nM sulprostone and are improved by 10 nM L-798,106 for 48 h via 
ELISA (*P<0.05, **P<0.001, n=12). (D) Western blotting analysis of uPAR in CaSki cells following 
treatment with 100 nM of each PGE2, sulprostone and L-798,106 for 48h (*P<0.05, n=3). Full-length 
blots are shown in Supplementary Figure 3. All data are shown as mean ± SD. *P<0.05 and **P<0.001 
are considered as significantly different after comparison between the stimulation group and the 
control group. 
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4.1.5 Expression of uPAR in cervical cancer tissues  
The in vitro studies imply the relevance of EP3 and uPAR, therefore, we further analyzed the 
expression of uPAR in 250 cervical cancer patients. uPAR staining was observed in the 
cytoplasm of 93.6% (234/250) of cervical cancer tissue samples, and the median IRS for 
cytoplasmic uPAR expression was 2.05 (Figure 5). The cut off of IRS 2 was obtained from 
receiver operator curve (ROC) analysis. To evaluate uPAR staining, we used metastatic colon 
carcinoma tissue with a very strong cytoplasmic expression of uPAR as negative and positive 
controls (Supplementary Figure 2A. B).  
    In the following analyses, we examined the correlation between uPAR expression and 
several clinical-pathological parameters such as T-status, N-status, M-status, grading, FIGO-
classification and the expression of oncoproteins by noticing the distribution of these 
parameters in our study group (Table 2). For positive uPAR expression in cervical cancer 
tissues, a significant negative correlation with pN (P=0.017, Rho=-0.156), p16 (P=0.05, Rho=-
0.13) and galectin-3 (P=0.002, Rho=-0.202) could be shown (Table 2). The percentage of 
uPAR positive staining cells was negatively associated with the intensity of wild-type p53 
staining in the cytoplasm (P=0.011, Rho=-0.184, data not shown), although no correlation 
between uPAR and wild-type nuclear p53 (P=0.118, Table 2) or between uPAR and mutant 
p53 in the nucleus (P=0.082, Table 2). A significant positive correlation between uPAR and 
histone H3 tri methyl K4 (H3K4me3) was also detected (P=0.041, Rho=0.134, Table 2). 
Although the EP3 antagonist could inhibit the expression of uPAR in CaSki cells, there was no 
significant correlation between uPAR expression and EP3 (P=0.822, Table 2) in cervical 
cancer specimens.  
    Also, we could show a significant negative correlation between the International 
Federation of Gynecology and Obstetrics (FIGO) status and uPAR expression (spearman’s-
rank correlation Rho=-0.165; P=0.012), suggesting that weak uPAR staining was correlated 
with a high FIGO stage (Table 2). Cervical cancer specimens demonstrated significantly 
decreased uPAR staining with a higher FIGO stage (P=0.046, Figure 6A). A total of 44.8% 
(112/250) of cervical cancer patients with FIGO stages I/II had a median IRS of 2.17 
compared to 17.6% of patients (44/250) with FIGO stages III/IV and with a median IRS of 
1.52 (Figure 6A).  
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Table 1. Clinical-pathological variables of the patients included in the study 
 
Clinical characteristics No./ Total No. % 
Age (Median) [years] 40.5  
Follow-up (Median) [months] 126.5  
No. of Positive Nodes   
0 151/250 60.4 
≥1 97/250 38.8 
Not available 2/250 0.8 
FIGO   
I and II 112/250 44.8 
III and IV 44/250 17.6 
Not available 94/250 37.6 
Tumor Grade   
I 21/250 8.4 
II 143/250 57.2 
III 78/250 31.2 
Not available 8/250 3.2 
Tumor Subtype   
Squamous 202/250 80.8 
Adenocarcinoma 48/250 19.2 
Survival (over 235 months)   
Right censured 190/250 76.0 
Died 49/250 19.6 
Not available 11/250 4.4 
 
  
                                                                                                                                            Results 
39 
 
Table 2. Staining results and correlation analysis 
 
Variables P Value Correlation  Coefficient 
Histology 0.247 0.076 
pT 0.117 -0.103 
pN 0.017* -0.156 
pM 0.308 -0.067 
Grading 0.397 0.056 
FIGO 0.012* -0.165 
EP3 0.822 -0.015 
E6 0.836 0.014 
p16 0.05* -0.130 
wild-type p53 
mutant p53 
0.118 
0.082 
-0.103 
-0.114 
MDM2 0.938 -0.005 
galectin-3 0.002* -0.202 
GPER 0.52 -0.042 
H3K9ac 0.121 -0.102 
H3K4me3 0.041* 0.134 
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Figure 5. uPAR immunohistochemical staining in cervical carcinoma. (A) Representative 
photomicrographs of uPAR staining in cervical squamous cell carcinoma (FIGO IIIB) with uPAR IRS 
score of 3. (B) Representative photomicrographs of uPAR staining in cervical squamous cell 
carcinoma (FIGO IIIB) with IRS score of 0. (C) Representative photos of uPAR immunohistochemical 
staining in adenocarcinoma (FIGO IIIA) with IRS score of 4. (D) Representative photos of uPAR 
immunohistochemical staining in adenocarcinoma (FIGO IVB) with IRS score of 0. The scale bars in 
the outer pictures equal 200 µm (10x magnification) and the scale bars in the inserts equal 100 µm 
(50x magnification). FIGO = the International Federation of Gynecology and Obstetrics.  
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Supplementary Figure 2. Positive and negative controls of uPAR staining (A.B). We used the 
metastatic colon carcinoma for positive and negative controls.  
 
4.1.6 Correlation of uPAR expression with OS of cervical cancer patients with 
FIGO Stages III and IV 
uPAR positivity in general was not related to overall survival (OS) in the non-stratified patient 
sample. However, when patients had been stratified according to FIGO stage, the high 
expression of uPAR was correlated with poor prognosis in OS rates in cervical patients with 
FIGO stages III/IV as shown in the Kaplan-Meier curve (P=0.047, Figure 6B). 
    Among all the 44 advanced cervical cancer patients (FIGO III/IV), 33 cases with squamous 
cell carcinoma had a median IRS of 1.12 and 10 cases with adenocarcinoma had a median IRS 
of 2.9, which shows no significant difference between these two histological subtypes 
(P=0.09). The subsequent survival analysis of the two main histological subtypes suggested 
that a significant negative correlation of uPAR with OS was observed in squamous cell 
carcinoma (P=0.006, Figure 6C), but not in cervix adenocarcinoma (P=0.536, Figure 6D). It 
implied that immunopositivity of uPAR is predictive for OS in cervical cancer patients of 
advanced stage (FIGO III/IV), especially among cases with squamous cell carcinoma. 
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Figure 6. The role of uPAR in the overall survival of cervical cancer patients. (A) Boxplot shows uPAR 
staining in cervical cancer patients with FIGO I and II is higher than in patients with FIGO III and IV 
(P=0.046); (B) High uPAR expression (IRS≥2) is associated with a shorter OS in advanced cervical 
cancer patients (FIGO III/IV) (P=0.047); (C) High uPAR expression (IRS≥2) is associated with a shorter 
OS of advanced patients in cervical squamous cell carcinoma (P=0.006); (D) uPAR survival function of 
cervical adenocarcinoma in patients with FIGO stages III/IV (P=0.536). FIGO= the International 
Federation of Gynecology and Obstetrics. 
 
4.1.7 Multivariate Cox regression analysis of uPAR 
Multivariate Cox regression analysis was performed to test which histopathological variables 
including uPAR expression, histology, tumor size (pT), nodal status (pN), tumor 
differentiation grade, FIGO-classification, and age were independent prognosticators for OS 
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in advanced cervical cancer patients (FIGO III/IV). Although no significant effect was detected 
for the histopathological variables, uPAR was nearly a promising prognosticator for advanced 
cervical cancer patient OS (P=0.067, Table 3). 
 
Table 3. Cox regression of clinical-pathological variables regarding overall survival 
 
Variable Significance Hazard Ratio 
of Exp (B) 
Lower 95% CI 
of Exp (B) 
Upper 95% 
CI of Exp (B) 
uPAR IRS 0.067 8.332 0.863 80.425 
Histology 0.222 5.182 0.370 72.505 
pT 0.231 2.056 0.632 6.687 
pN 0.987 4553661.9 0.000 - 
pM 0.314 0.193 0.008 4.734 
Grading 0.255 3.664 0.391 34.350 
FIGO 0.962 0.974 0.331 2.865 
Age 0.588 1.031 0.922 1.153 
 
IRS= Immunoreactive score, pN= lymph node stage, pT= tumor stage, pM= distant metastasis stage, 
FIGO= the International Federation of Gynecology and Obstetrics.  
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4.2 EP3 signaling in unexplained recurrent miscarriages (uRM)  
4.2.1 Clinical data of the uRM group and control group 
The mean age of the women in the uRM group was 37.76±4.88 years and of the control 
group 35.78±5.88 years (P=0.41). Mean gestational age of the uRM group was 9.09±2.17 
weeks and of the control group 9.71±1.88 weeks (P=0.66). The gravidity times were 
decreased in patients with uRM (3.11±1.08) compared to healthy controls (3.42±1.90, 
P=0.002), while the parity times of two groups showed no significant differences (0.94±0.94 
vs 1.63±1.12, P=0.35). Demographic and clinical data are illustrated in table 1. 
 
Table 1: Demographic and clinical characteristics of the study population. Values are 
represented as mean± SD; the range is shown in parentheses. 
 
4.2.2 Expression of COX-2, EP3 and Gi1 in the placenta of women with uRM 
and controls  
Expression of COX-2, EP3 and Gi1 was identified in the cytoplasm of cells in the syncytium 
and the decidua of first-trimester pregnancies in both the uRM group and the control group 
(Figure 1A-R). A significant increase in the expression of COX-2 could be observed in the 
syncytium of the uRM group in comparison to the control group (IRS 8.73 vs 5.59; P=0.007, 
Figure 1A.B.E). COX-2 expression in the decidua of the uRM group was also significantly 
increased in comparison to the control group (IRS 4.29 vs 2.00; P=0.004, Figure 1C.D.F).  
     Expression of both EP3 and Gi1 in the decidua was significantly upregulated in patients 
with uRM compared to normal controls (Figure 1L.R), but no significant changes of EP3 and 
Gi1 could be observed in the syncytium (Figure 1K.Q). In the uRM group, EP3-staining in the 
Characteristic Normal pregnancy 
n=19 
uRM 
n=19 
P Value 
(t-Test) 
maternal age (years) 35.78±5.88 (25-46) 37.76±4.88 (30-44) 0.41 
gestational age (weeks) 9.71±1.88 (6-13) 9.09±2.17 (4-12) 0.66 
gravidity 3.42±1.90 (1-7) 3.11±1.08 (2-5) 0.002 
parity 1.63±1.12 (0-4) 0.94±0.94 (0-3) 0.35 
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decidua was more intense with a mean IRS of 4.15, which is higher than the mean IRS of the 
control group (IRS=2.22, P=0.001, Figure 1I.J.L). EP3-staining in the syncytium of the uRM 
group was similar to the control group (IRS 5.75 vs 6.32; P=0.350, Figure 1G.H.K).  Gi1-
staining was stronger in the decidua of the uRM group compared to the control group (IRS 
4.48 vs 2.89; P=0.008, Figure 1O.P.R). There was no significant staining difference for Gi1-
staining in the syncytium between the uRM group and the control group (IRS 5.27 vs 4.47; 
P=0.292, Figure 1M.N.Q). Both positive and negative controls are shown in the supplemental 
Figure 1. 
     Expressions of COX-2, EP3 and Gi1 were all increased in the decidua of patients with uRM 
compared to healthy controls, implying that a correlation could exist between them. We 
further analyzed the correlation of each two of these three components in the decidua. 
Unfortunately, there was no statistically significant correlation between COX-2 and EP3 
expression (r=-0.059; P=0.788), neither for EP3 and Gi1 (r= 0,251; P= 0.261) nor for COX-2 and 
Gi1 (r=0.158, P=0.450) in the decidua. 
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Figure 1. Immunohistological analyses of COX-2, EP3 and Gi1 expression in placentas of uRM patients 
(B.D.H.J.N.P) and healthy controls (A.C.G.I.M.O) from the first trimester were measured via IRS 
score. In the syncytium, the stainings of COX-2 (A.B), EP3 (G.H) and Gi1 (M.N) are compared between 
the uRM patients and controls, which are represented as box-plots (E.K.Q). In the decidua, the 
expressions of COX-2 (C.D), EP3 (I.J) and Gi1 (O.P) are increased in uRM patients compared to 
controls, which are represented as box-plots (F.L.R).  The range between the 25th and 75th percentiles 
is represented by the boxes with a horizontal line at the median. The bars show the 5th and 95th 
percentiles. Dots indicate values more than 1.5 box lengths from the 75th percentile. Magnification 
x10 lens, scale bar= 200 µm. uRM=unexplained recurrent pregnancy losses. 
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Supplementary Figure 1. Positive and negative controls of COX-2 (A.B), EP3 (C.D), and Gi1 (E.F). For 
positive control of COX-2 and Gi1, third trimester placentas are used and colon is used as positive 
control for EP3. 
 
4.2.3 Localization of COX-2, EP3 and Gi1 in the decidua of first-trimester 
placentas  
As the decidua consists of maternal decidual stroma cells and extravillous trophoblasts, 
double immunofluorescence was used to identify COX-2, EP3 and Gi1-expressing cells. 
Prolactin was used as a marker for stromal cells and HLA-G as a maker for trophoblasts, 
respectively. COX-2 was co-expressed with prolactin predominantly in the cytoplasm of 
stromal cells (Figure 2A.B.C). Both EP3 (Figure 2D.E.F) and Gi1 (Figure 2H.I.G) were co-
expressed with HLA-G in the cytoplasm of extravillous trophoblasts. Gi1 was expressed 
especially beneath the cell membrane of extravillous trophoblasts (Figure 2G). Since co-
expression of COX-2, EP3 and Gi1 was similar in both the uRM and control group, we only 
showed pictures of the uRM group. 
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Figure 2. Localization of COX-2, EP3 and Gi1 is shown in the decidua of patients with uRM. COX-2 is 
co-expressed with prolactin, which is a specific marker for stromal cells (A.B.C). EP3 is co-expressed 
with HLA-G, which is a specific marker for extravillous trophoblasts (D.E.F). Gi1 is co-expressed with 
HLA-G in extravillous trophoblasts (G.H.I). Co-expression of COX-2, EP3 and Gi1 is shown with . 
Magnification x63, scale bar= 20 µm. 
 
4.2.4 Influence of PGE2, sulprostone and L-798,106 on the expression of EP3 
signaling in JEG-3 cells in vitro 
In order to investigate the mechanism of the EP3 signaling in extravillous trophoblasts of 
uRM in vitro, JEG-3 and HTR-8/SVneo cells were used and stimulated with different 
concentrations of PGE2, EP1/EP3 agonist (sulprostone) and EP3 antagonist (L-798,106) for 48 
hours.  
                                                                                                                                            Results 
49 
 
Firstly, the MTT assay was used to assess the viability of JEG-3 cells after 48 hours of 
treatment with 0.1, 1, 10, 100, 1000 nM and 10 µM PGE2, L-798,106 or the vehicle control 
(DMSO, 0.1%). 10 nM PGE2 and 10 nM L-798,106 significantly increased viability of JEG-3 
cells compared to control group (P<0.05, data not shown). 
     For JEG-3 cells, the production of β-hCG was suppressed from 16.33±3.30 mIU/ml in the 
vehicle to 12.20±1.76 mIU/ml by 10 nM PGE2 (P=0.046), while its concentration was not 
significantly influenced by 0.1 nM and 1 nM PGE2 (Figure 3A). Additionally, β-hCG expression 
was inhibited from 16.33±3.30 mIU/ml in the vehicle to 10.19±1.79 mIU/ml and 10.99±1.15 
mIU/ml when sulprostone concentration was 1 nM and 10 nM (P=0.028, P=0.028, 
respectively, Figure 3A). However, β-hCG levels were not altered by L-798,106 independent 
of the concentration of 0.1 nM, 1 nM or 10 nM (Figure 3A). 
     Progesterone expression of JEG-3 cells was downregulated by PGE2, sulprostone and L-
798,106, independent of different concentrations (0.1 nM, 1 nM and 10 nM) in comparison 
to the vehicle after 48 hours (P= 0.028, each) (Figure 3B). 
     PAI-1 levels were significantly altered 34% higher through 10 nM sulprostone than the 
vehicle, while no significant changes of PAI-1 expression were detected through 10 nM PGE2 
and 10 nM L-798,106 (Figure 3C). 
     Western blotting was utilized to access the expression of EP3, Gi1 and p-ERK1/2 in JEG-3 
cells stimulated by PGE2 and L-798,106, 10 nM each (Figure 3D). The molecular weight of EP3 
is 37kDa and of Gi1 it is 40kDa. EP3 expression was decreased by 31.8% after treatment with 
10nM L-798,106 compared to the vehicle group (P=0.008, Figure 3D). Gi1 expression was 
increased by 12.4% through 10 nM PGE2 (P=0.012, Figure 3E). The molecular weights of p-
ERK1/2 are 44 and 42kDa.  
JEG-3 cells were incubated with 0.5% DMSO for 1, 2, 6, 12, 24, 48 hours and the results 
showed there was the strongest expression of p-ERK1/2 after 1 hour incubation 
(Supplementary Figure 2A). After 1 hour incubation, the expression of p-ERK1/2 was 
stimulated by 18.3% through 10 nM sulprostone compared to the vehicle (P=0.035), while 
no significant change was detected in the group treated with 10 nM PGE2 or L-798,106 
(Figure 3F). 
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Figure 3. Expression of β-hCG, progesterone, plasminogen activator inhibitor (PAI-1), EP3, Gi1, p-
ERK1/2 and p53 in JEG-3 cells after incubation with PGE2, the EP1/EP3 agonist (sulprostone) and EP3 
antagonist (L-798,106). β-hCG, progesterone and PAI-1 expression levels were measured via ELISA 
(each group n=6). EP3, Gi1, p-ERK1/2 and p53 expression extracted from JEG-3 cells were detected by 
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western blotting, following treatment with PGE2 (10nM) and L-798,106 (10nM) for 48h (n=3). All data 
is shown as mean +/-SD and statistically significant differences (P < 0.05) between individual 
treatment groups and the vehicle are marked with an asterisk. 
 
 
 
 
Supplementary Figure 2. Representative western blots. (A) Representative western blots of p-ERK1/2 
expression when JEG-3 and HTR-8/SVneo cells were incubated with 0.5% DMSO for different time 
periods. (B) Representative western blots for the expression of EP3, Gi1, p-ERK1/2 and p53 in JEG-3 
and HTR-8/SVneo cells stimulated by 10 nM of each PGE2, sulprostone and L-798,106. 
 
 
 
 
 
 
 
 
 
                                                                                                                                            Results 
52 
 
4.2.5 Influence of PGE2, sulprostone and L-798,106 on the expression of EP3 
signaling in HTR-8/SVneo cells in vitro 
HTR-8/SVneo cells were incubated with PGE2, sulprostone and L-798,106 at a concentration 
of 10 nM and 100 nM respectively. β-hCG levels of HTR-8/SVneo cells were down-regulated 
through PGE2, sulprostone and L-798,106 for all concentrations after 48 hours (P<0.05, each) 
(Figure 4A). Progesterone levels could not be detected in the supernatants of HTR-8/SVneo 
cells. PAI-1 levels were reduced 3.7% through 10 nM L-798,106 than the vehicle, while no 
significant changes of PAI-1 expression were detected through 10 nM sulprostone (Figure 
4B). 
     In western blotting, EP3 expression was increased by 11.6% through 10 nM PGE2 
(P=0.011, Figure 4C) and decreased by 25.9% through 10 nM L-798,106 compared to the 
vehicle (P=0.008, Figure 4C). Gi1 expression was increased by 22.5% through 10 nM 
sulprostone (P=0.046, Figure 4D), while no significant changes were observed through 10 nM 
PGE2. The expression of p-ERK1/2 decreased when the incubation time with 0.5% DMSO is 
increased from 1 to 48 hours and the strongest expression of p-ERK1/2 was after 1 hour 
incubation (Supplementary Figure 2A). The expression of p-ERK1/2 was inhibited by 21.8% 
after treatment with 10 nM L-798,106 for 1 hour compared to the vehicle group (P=0.011, 
Figure 4E).The molecular weight of p53 is 53 kDa, and its expression was stimulated by 
17.0% through 10 nM PGE2 (P=0.028, Figure 4F) and by 24.5% through 10 nM sulprostone 
(P=0.028, Figure 4F). 
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Figure 4. Expression of β-hCG, EP3, Gi1, p-ERK1/2 and p53 in HTR-8/SVneo cells after incubation with 
PGE2, the EP1/EP3 agonist (sulprostone) and EP3 antagonist (L-798,106). The levels of β-hCG and PAI-
1 were measured via ELISA (each group n=6). EP3, Gi1, p-ERK1/2 and p53 expression extracted from 
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HTR-8/SVneo cells were detected by western blotting, following treatment with PGE2 (10nM), 
sulprostone (10nM) and L-798,106 (10nM) for 48h (n=3). All data are shown as mean ± SD and 
statistically significant differences (P < 0.05) between individual treatment groups and the vehicle are 
marked with an asterisk.
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5 Discussion 
5.1 EP3 signaling pathway in cervical cancer 
5.1.1 The EP3 signaling pathway is induced in cervical cancer 
High expressions of COX-2 and PGE2 have been identified in cervical carcinoma. The research 
group of Sales et al. suggested that PGE2 regulates the function of cervical cancer cells via 
cyclic adenosine monophosphate (cAMP)-linked EP2/EP4 signaling pathway82,83. In our latest 
publication, we found that high expression of EP3 (IRS≥2) in both squamous cell carcinoma 
and adenocarcinoma is associated with poor prognosis in overall survival rates of 250 
cervical cancer patients91. It suggests that EP3 signaling pathway also participates in the 
carcinogenesis of cervical cancer. Therefore, in the present study, we aimed to explore the 
possible mechanism of how EP3 signaling pathway plays its role in cervical cancer cells. 
Literatures have shown that EP3 regulates the carcinogenesis in numerous cancers 
through different signaling pathways. EP3 promotes the cell growth of CCLP1 human liver 
cancer cells by coupling to Gs protein and activating cAMP-protein kinase A (PKA)136. EP3 
increases the migration of HCA-7 human colon cancer cells through the activation of 
phosphatidylinositol 3-kinase (PI3K) and the phosphorylation of extracellular signal-
regulated kinases 1/2 (ERK1/2) signaling pathway137. Sulprostone improves the invasiveness 
of human doxorubicin-resistant MCF-7 breast cancer cells via enhancing the mRNA of matrix 
metalloproteinases (MMP)-2, MMP-9 and uPA138. On the contrary, sulprostone was 
suggested to decrease the proliferation of human prostate cancer cells139 and the selective 
EP3 agonist ONO-AE-248 inhibits the viability of HCA-7 human colon cells140. In vitro studies, 
we proved that the EP1/EP3 agonist (sulprostone) stimulated the proliferation and migration 
of both CaSki and Hela cells, which is in line with the previous finding that EP3 is a negative 
prognosticator in cervical cancer patients91. We observed that the expression of EP1 was not 
altered by PGE2, sulprostone or L-798,106, while the expression of EP3 was inhibited by the 
specific EP3 antagonist L-798,106. EP3 is mainly coupled to Gi to inhibit AC, leading to the 
decreased expression of cAMP. Regulation of Gi by the natural EP3 ligand PGE2 seems to be 
in favour for an active EP3 signaling in cervical cancer cells, although there is no influence of 
sulprostone or L-798,106 on Gi expression in these cells. These findings suggest that EP3-Gi-
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cAMP might not be the primary signaling pathway functioning in cervical cancer cells, 
although EP3 was proved to be a key hint in the carcinogenesis of cervical cancer.  
In HCA-7 human colon cells, the phosphorylation of ERK1/2 was only mediated by EP3 
receptor enhancing migration137. EP3 induces the mRNA expression of vascular endothelial 
growth factor (VEGF) through phosphorylation of ERK1/2 and activation of PI3K signaling, 
which contributes to tumor-related angiogenesis141. ERK1/2 are members of the mitogen-
activated protein kinase superfamily that can mediate cell proliferation and apoptosis142. In 
our investigations, we showed that the expression of phosphorylated-ERK1/2 (p-ERK1/2) 
was upregulated by sulprostone in Hela cells and downregulated by L-798,106 in CaSki cells. 
Additionally, ERK1/2 is an upstream regulator of PAI-1 gene transcription132. The activation 
of EP3 signaling induces increased expression of p-ERK1/2 in cervical cancer cells, which 
could result in increased PAI-1 gene expression. It implies that EP3 might indirectly regulate 
the function of cervical cancer cells via induction of PAI-1 instead of cAMP signaling.  
5.1.2 Plasminogen activating system is stimulated by EP3 in cervical cancer 
Our data demonstrated that sulprostone increased the production of PAI-1 in the 
supernatants of both CaSki and Hela cells, which is in good agreement with the study that 
PGE2 utilizes EP1/EP3 receptor to increase PAI-1 levels in cardiac fibroblasts122. It has been 
well-known that high expression of PAI-1 is correlated with worse overall and disease-free 
survival and is an independent prognosticator in cervical cancers126,143. High expression of 
PAI-1 can protect cervical tumor cells from degradation126. Furthermore, PAI-1 enhances 
tumor cell proliferation by encouraging S-phase entry144 and increases migration by binding 
uPA/uPAR complex145. PAI-1/uPA/uPAR/ low density lipoprotein receptor-related protein 
(LRP)/integrin complexes are initiating an “adhesion–detachment–re-adhesion” cycle to 
promote tumor cell migration145,146. Interestingly, we also observed that L-798,106 could 
also increase the secretion of PAI-1 in the supernatants of both cell lines, which could imply 
that EP3 activates at least one signaling pathway except for plasminogen activating pathway 
and needs further investigations. 
Apart from PAI-1, uPA and uPAR are also useful for predicting the prognosis of cervical 
cancer. Jing et al. suggested that the soluble uPAR in serum is a prognosis marker in cervical 
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cancer as well as a tumor biomarker for clinical diagnosis and treatment147. Sasaki et al. 
found that overexpression of uPAR mRNA is related to a shorter disease-free survival rate of 
cervical cancer patients, however, the immunohistochemical staining of uPAR was not very 
intense148. Using immunohistochemistry, we could demonstrate for the first time that uPAR 
expression (IRS≥2) was associated with a poor OS of cervical cancer patients with advanced 
stage (FIGO III/IV). uPA is useful for predicting the metastatic potential of lymph nodes in 
cervical cancer patients149-151, implying that both uPA and uPAR are valuable biomarkers for 
advanced cervical carcinomas. The negative correlation of uPAR with OS of patients is 
significant in squamous cell carcinoma but not in cervix adenocarcinoma, which could be due 
to the smaller number of patients with adenocarcinoma (n=10). This result also agrees with 
multivariate Cox regression analysis, indicating that with a large scale of specimens, uPAR 
could be a promising prognosticator for OS of advanced cervical cancer patients.  
5.1.3 Correlation of uPAR with new biomarkers of cervical carcinomas 
Several biomarkers has been analyzed for OS in cervical cancer patients in the last year, such 
as p16152, MDM2152, galectin-3152, H3K9ac153 and H3K4me3153. Therefore, we also performed 
the correlation analysis of uPAR with these oncoproteins in the same cervical cancer 
patients. The positive correlation of histone H3 tri methyl K4 (H3K4me3) and uPAR 
expression in our study is in accordance with the finding that H3K4me3 is related to poor 
prognosis in cervical cancer patients and is an independent marker of relapse-free 
survival153. Additionally, we found that a negative correlation of uPAR with both galectin-3 
and p16 in cervical cancer patients. Stiasny et al. showed that galectin-3 expression was 
correlated with a shorter survival time in cervical cancer patients expressing no or very low 
p16152. In hepatocellular carcinoma cells, the silencing of galectin-3 attenuated the 
expression of uPAR and inhibited the proliferation, migration and invasion154. This study also 
agrees with our detections that low expression of uPAR was correlated with longer survival 
time in cervical cancer patients with advanced stage. E6 proteins induce rapid degradation of 
tumor suppressor protein p53 to prevent the host cell from inducing apoptosis155. Besides, 
overexpression of wild-type p53 causes the activation of ERK1/2142 and both ERK1/2 and p53 
are upstream regulators for PAI-1 transcription132. We found that wild-type p53 in the 
cytoplasm was downregulated in the cervical cancer cells that showed high expression of 
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uPAR, suggesting p53 might move into the nucleus from the cytoplasm to induce PAI-1 
transcription. 
    One limitation of this investigation is that it is a retrospective study, which analyzes the 
data of the patients who had undergone surgery in one single hospital from 1993 to 2002. A 
multi-center prospective study should be carried out for further research.  
In the part of cervical cancer, the findings of this study indicate that in human cervical 
cancer cells, the EP3 receptor is able to regulate cell proliferation and migration through 
phosphorylation of ERK1/2 and transcription of PAI-1. Further, it was observed that 
overexpression of uPAR was associated with poor prognosis in cervical cancer patients with 
advanced stage (FIGO III/IV) and therefore suggested that uPAR may represent a novel 
therapeutic target for the treatment of this malignancy. Several uPAR-targeted therapies 
already exist, such as specific uPA inhibitors, anti-uPAR antibodies blocking uPAR 
downstream signaling, and blockers breaking the interactions between uPAR and its binding 
partners156. In this investigation, L-798,106 could decrease the expression of both EP3 and 
uPAR in CaSki cell line, therefore a functional antagonist of EP3 could also be a promising 
agent for cervical cancer treatment. 
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Figure 7. Schematic diagram of EP3 signaling in human cervical cancer cells. EP3 signaling regulates 
the proliferation and migration of cervical cancer cells through the plasminogen activating (PAI-
1/uPA/uPAR) system. The EP3 agonist (sulprostone) coupling EP3 receptor stimulates 
phosphorylation of extracellular signal-regulated kinases (p-ERK1/2). Then the p53 in the cytoplasm 
translocates to the nucleus, inducing an increased transcription of plasminogen activator inhibitor 
type 1 (PAI-1). In addition, transforming growth factor-β 1 (TGF-β 1) can also induce PAI-1 gene 
expression via the rapid generation of reactive oxygen species (ROS), phosphorylation of ERK1/2 and 
the mobilization of p53 signaling132. The elevated expression of PAI-1 leads to a binding with 
urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR), and then the trimeric PAI-
1/uPA/uPAR complex is recognized by the low density lipoprotein receptor-related protein (LRP) and 
endocytosed together with integrins to promote tumor cells migration145,146. Cytoplasmic p53 is 
decreased in the cervical cancer cells with high expression of uPAR, which is correlated with poor 
prognosis in overall survival rates of cervical cancer patients with advanced FIGO stages (III/IV). The 
EP3 antagonist (L-798,106) can inhibit the expression of p-ERK1/2 and uPAR.  
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5.2 EP3 signaling in unexplained recurrent miscarriages (uRM)  
5.2.1 COX-2-PGE2-EP3 signalling pathway in uRM patients 
An increased inflammatory reaction can contribute to uRM157. PGE2 plays an important role 
in regulating immune balance and angiogenesis during implantation and early pregnancy157 
and it is able to stimulate inflammatory reactions via EP3158. The role of PGE2 receptor 
signalling in the mechanism of uRM still remains unknown. After investigating the effects of 
EP3 in cervical cancer carcinogenesis, our research group also explored EP3 signalling 
pathway in pathological mechanisms of uRM. During normal placentation, extra villous 
trophoblast cells invade the uterus in a tumor-like manner and engraft to the maternal blood 
vessels. 
5.2.2 COX-2 is highly expressed in the stromal cells of uRM patients 
As the rate-limiting enzyme for PGE2 synthesis, COX-2 is expressed by human endometrial 
stroma cells100, which is in line with our finding. COX-2 is involved in blastocysts implantation 
in the early pregnancy phase101. So far, a small number of literatures exist concerning COX-2 
expression levels in uRM with conflicting conclusions. Wang et al. and his research group 
reported that decreased expression levels of COX-2 have been found in the chorionic villi of 
women with uRM than healthy controls101, and Hua et al. showed the similar result in mice 
embryos with the animal model of autoimmune-type recurrent miscarriages102. Our result is 
in accordance with another study group of Banerjee et al. who detected that the expression 
levels of COX-2 are upregulated in the endometrium of uRM women in comparison to 
healthy controls104. In this study, expression of both PGE2 and pro-inflammatory cytokines is 
also increased in the endometrium of uRM women, such as interleukin 1β (IL-1β), tumor 
necrosis factor α (TNF-α), interferon γ (IFN-γ), and transforming growth factor β1 (TGF-
β1)104. IL-1, TNF-α and IFN-γ belong to Th1 cytokines, and this Th1 predominance has been 
known to be one of the immunological reasons for uRM105. TNF-α can induce COX-2 gene 
expression in first-trimester trophoblasts106, indicating the pro-inflammatory cytokine can be 
a positive feedback for COX-2 expression. 
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5.2.3 PGE2 is induced in uRM patients 
The effects of PGE2 on trophoblast cells are also contradictory for in vivo and in vitro studies. 
Ryantova et al. observed that PGE2 levels in the cervical ovulatory mucus are increased in 
patients with uRM110, which is mainly caused by overexpressed levels of COX-2. However, 
Biondi et al. proved that PGE2 inhibits cell proliferation and migration of HTR-8/SVneo cells 
via upregulating cAMP159, while Horita et al. demonstrated that PGE2 stimulates migration of 
HTR-8/SVneo cells via leukemia inhibitory factor (LIF)160. We found that PGE2 inhibited the 
production of β-hCG and progesterone in JEG-3 cells and the production of β-hCG in HTR-
8/SVneo cells. Low expression levels of β-hCG and progesterone in the serum have been 
used to serologically diagnose early pregnancy losses161,162. Intravaginal PGE2 decreases the 
excretion of β-hCG in the urine and progesterone in the plasma, which is in good agreement 
with our study that high expression levels of PGE2 in the placenta are detrimental to 
pregnancy maintenance.  
5.2.4 The expression of EP3 is induced in uRM patients 
Prostaglandin E2 receptors (EP1-4) are G protein-coupled receptors that are all activated by 
PGE2 with various signalling pathways. Yamazaki et al. (2006) indicated that mRNA and 
protein expression of COX-2 and EP3 are increased in the placenta of rats after ischemia-
reperfusion, which is associated with intrauterine growth restriction163. In our study, we 
observed that EP3 expression was mainly expressed in the extravillous trophoblasts and 
increased in extravillous trophoblast cells of uRM patients compared to normal pregnancies 
in the first trimester placenta. Trophoblast invasion takes place in a low oxygen environment 
in normal pregnancies, while shallow trophoblast implantation and ischemia in the placenta 
could lead to miscarriages. It is difficult to conclude that induced EP3 signalling pathway is 
the consequence or the cause of uRM. The EP3 gene formed nine distinct mRNAs encoding 
at least eight EP3 isoforms19, and the anti-EP3 antibody applied in our study could detect the 
protein region within the internal sequence amino acids 360-409. It might partly explain 
different band signals of EP3 in JEG-3 and HTR-8/SVneo cells for in vitro studies.  
    Furthermore we investigated that sulprostone (an EP1/EP3 agonist) inhibited the secretion 
of β-hCG and progesterone in JEG-3 cells and β-hCG expression in HTR-8/SVneo cells. 
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Sulprostone, as a PGE2 analog, can be used for medical termination of early pregnancy164. A 
reduced production of both β-hCG and progesterone is detrimental to blastocyst growth and 
pregnancy maintenance 165. However, Biondi et al. (2006) reported that PGE2 inhibited cell 
proliferation and migration of HTR-8/SVneo cells via EP2 and EP4 receptors instead of EP3159. 
In order to explore the exhaustive mechanisms of membrane receptors of PGE2 in the 
placenta of uRM, the remaining membrane receptors of PGE2 (EP1, EP2 and EP4) still need to 
be investigated, and the EP1 receptor represents an important receptor we have been 
focused on in a recent publication166. 
5.2.5 The effects of EP3 signaling in uRM patients 
The activation of G protein α stimulator (Gs) stimulates the activity of adenylate cyclase (AC), 
enhances intracellular levels of cyclic adenosine monophosphate (cAMP) and activates 
protein kinase A (PKA), and this cAMP/PKA signaling cascade is a vital second messenger 
pathway for steroid biosynthesis167. G protein α inhibitor (Gi) inhibits AC, contributing to 
decreased levels of cAMP and inhibited activity of PKA168. We detected that the expression 
of Gi1 was mainly expressed in extravillous trophoblasts and upregulated in the decidua of 
uRM patients. It indicates that the cAMP/PKA signaling pathway may be inhibited in the 
extravillous trophoblasts of uRM. cAMP increases α-hCG gene transcription in villous 
trophoblasts by interacting with the cAMP response element-binding protein (CREB)169. PKA 
stimulates progesterone synthesis in the human placenta by phosphorylation of enzymes170. 
We found that both PGE2 and sulprostone stimulated the expression of Gi1 and suppressed 
the production of β-hCG and progesterone, which could be caused by the stimulated EP3/Gi1 
and inhibited cAMP/PKA signaling. 
Interestingly, we found the expression of PAI-1 was upregulated by sulprostone in JEG-3 
cells, which is known as the main inhibitor of fibrinolysis171. High plasma levels of PAI-1 and 
high PAI activities are prevalent in women with uRM in comparison to healthy controls172. 
PGE2 utilizes EP1/EP3 receptor to increase PAI-1 levels in cardiac fibroblasts, resulting in 
elevated fibrin deposition in aortic stenosis122. TGF-β1 can induce PAI-1 gene expression by 
phosphorylation of extracellular signal regulated kinases (ERK1/2) and p53132. The expression 
of p53 is upregulated in chorionic villi of RPL patients compared to healthy controls173. We 
found that sulprostone stimulated the expression of phosphorylated-ERK1/2 (p-ERK1/2) in 
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JEG-3 cells and the expression of p53 in HTR-8/SV neo cells. Additionally, the expression of p-
ERK1/2 was inhibited by EP3 specific inhibitor L-798,106 in HTR-8/SV neo cells. The 
activation of EP3 signalling induces increased expression of p-ERK1/2 and p53 in extravillous 
trophoblasts, which results in increased PAI-1 gene expression and an imbalance of 
extracellular matrix degradation during first-trimester pregnancies. Both the in vivo study of 
Yamazaki et al163 and also our study suggest that under pathological circumstances large 
differences in EP3 expression in the placenta can be observed. In contrast, only small 
magnitude changes of EP3 and PAI-1 were detected in our cell culture studies. It implies that 
trophoblast cells in vitro can partly mimic the in vivo delicate environment, however it still 
cannot replace the complex physical milieu of the placenta. Therefore, in vivo investigations 
of EP3 regulation in animal models or observational studies in humans should be the focus in 
future. 
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Figure 5. EP3 signaling is induced in the extravillous trophoblasts of uRM patients. Arachidonic 
acid is metabolized by COX-2 into PGH2, which is converted into multiple prostaglandins, such as 
PGE24. PGE2 acts through different membrane receptors (EP1-4)174. In the placenta of uRM patients, 
enhanced levels of COX-2 might be the reason for increased PGE2 expression. PGE2 coupling with EP3 
induces Gi1 and reduces cAMP, which can eventually lead to a downregulation of β-hCG and 
progesterone and an upregulation of PAI-1. The decreased cAMP/PKA signaling inhibits the secretion 
of progesterone via PKA170 and the transcription of β-hCG via CREB169. The activated EP3/Gi1 can 
stimulate p-ERK1/2 and p53, which eventually enhance PAI-1 gene transcription132. These changes 
could prevent trophoblast implantation and placentation, finally causing recurrent pregnancy losses. 
Abbreviation: COX-2, cyclooxygenase-2; PGH2, prostaglandin H2; PGE2, prostaglandin E2; EP, PGE2 
receptor; Gq, Gprotein alpha q; Gs, G protein alpha stimulator; Gi1, G protein alpha inhibitor 1; cAMP, 
cyclic adenosine monophosphate; p-ERK1/2, phosphorylated extracellular signal–regulated kinases 
1/2; PKA, protein kinase A; CREB, cAMP response element-binding protein; PAI-1, plasminogen 
activator inhibitor type 1; uRM, unexplained recurrent miscarriages.  
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6 Summary 
6.1 Role of EP3 signaling in the carcinogenesis of cervical cancer 
Elevated expression of COX-2 and PGE2 are found in numerous cancers and are associated 
with tumor development and progression. Although epidemiological, clinical and preclinical 
studies have shown inhibiting of PGE2 synthesis through NSAIDs or COX-2 inhibitors has the 
potential for cancer prevention and treatment, the side effects of inhibiting COX-2 functions 
have limited their use. Therefore, it is urgent for exploring novel targets and effective 
inhibitors which COX-2 activity may be reduced without inducing any reverse effects. In 
recent years, extensive efforts have gone into investigating the mechanism of PGE2 and EP 
receptors in health and disease.  
    In our investigation concerning EP3 signaling in cervical cancer, the EP3 receptor can 
regulate cell proliferation and migration through modulation of the plasminogen activating 
pathway in human cervical cancer cells. In vitro studies, EP1/EP3 agonist sulprostone 
stimulated tumor cells growth and migration in both CaSki and HeLa cells, while the EP3 
specific antagonist (L-798,106) inhibited the expression of EP3 in CaSki cells without affecting 
EP1 expression. At the same time, the expression of phosphorylated extracellular signal-
regulated kinases (ERK1/2) was upregulated by sulprostone and was downregulated by L-
798,106. Sulprostone increased the levels of PAI-1 in the supernatants of both CaSki and 
Hela cells via p-ERK1/2 and p53, implying a correlation might exist between EP3 signaling 
and plasminogen activating system in tumor development. In vivo studies showed that the 
overexpression of uPAR was associated with poor prognosis in cervical cancer patients with 
FIGO stages III and IV, which suggests that uPAR may represent another novel therapeutic 
target for the treatment apart from the EP3 receptor. L-798,106 could decrease the 
expression of both EP3 and uPAR in CaSki cells, which could be a promising agent for cervical 
cancers, especially for squamous cervical carcinoma. 
6.2 Role of EP3 signaling in the pathological mechanism of uRM 
In the study about recurrent miscarriages, we confirmed that enhanced levels of COX-2 were 
found in stromal cells of the placenta in unexplained RM. PGE2 in combination with the EP3 
receptor in extravillous trophoblasts contributed to a decreased production of β-hCG and 
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progesterone via Gi1 and AC, thus contributing to reduced levels of cAMP and deactivated 
activity of PKA. We also proved a crosstalk between EP3 signaling and plasminogen 
activating system in the pathological mechanism of RM. The activated EP3/Gi1 can enhance 
PAI-1 gene expression through stimulating p-ERK1/2 and p53. Upregulated production of 
PAI-1 can inhibit extracellular matrix degradation, contributing to intervillous fibrin 
deposition in the maternal-fetal interface. Downregulated secretion of β-hCG and 
progesterone and upregulated expression of PAI-1 could prevent trophoblast implantation 
and placentation, causing failed pregnancy maintenance. We explored that the EP3 
antagonist (L-798,106) caused downregulated EP3 expression without influencing the β-hCG 
expression in JEG-3 cells. It indicates that L-798,106 might be a ‘potential therapeutic 
candidate’ for the treatment of unexplained RM.  
    In conclusion, EP3 signaling pathway plays a vital role in the cancer development of 
cervical cancer and the pathological mechanism of recurrent miscarriages via p-ERK1/2 and 
PAI-1. The strong connection between EP3 signaling and plasminogen activating system 
exists in both diseases and L-798,106 can effectively inhibit the key factors in the crosstalk. 
Future studies should apply animal models to examine the effects of L-798,106 or more 
specific EP3 antagonist on inhibiting the inflammatory reactions in cervical cancer and RM. 
Attention should also be put on the additional membrane receptors of PGE2 (EP1, 2 and 4) 
and other members of Gi family (Gi2 and Gi3) in cancer development and RM.
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7. Zusammenfassung 
7.1 Die Rolle des EP3 Signalwegs in der Karzinogenese des Cervixkarzinoms 
Eine erhöhte Expression von COX-2 und PGE2 wurde in zahlreichen Karzinomentitäten 
gefunden und ist mit der Entstehung und Progression von Tumoren assoziiert. Obwohl 
epidemiologische, klinische und präklinische Studien gezeigt haben, dass eine Inhibition der 
PGE2 Synthese durch NSARs oder COX-2-Inhibitoren Potential für die Prävention und 
Therapie von Karzinomen besitzt, limitierten bisher die Nebenwirkungen von COX-2-
Inhibitoren deren Nutzung. Aus diesem Grund ist es notwendig, neue Targets und effektive 
Inhibitoren zu untersuchen, mit welchen die COX-2 Aktivität reduziert werden kann, ohne 
entgegengesetzte Wirkungen zu induzieren. In den letzten Jahren wurden umfassende 
Untersuchungen vorgenommen um den Mechanismus von PGE2 und EP Rezeptoren zu 
eruieren. 
    Unsere Untersuchungen bezüglich des EP3 Signalweges im Cervixkarzinom haben gezeigt, 
dass der EP3 Rezeptor in der Lage ist, die Zellproliferation und –migration durch Modulation 
des Plasminogen-aktivierenden Signalwegs in humanen Cervixkarzinomzellen zu regulieren. 
In in vitro Studien wurde nachgewiesen, dass Sulprostone, ein EP1/EP3 Agonist, das 
Tumorzellwachstum und die Tumorzellmigration in CaSki- und HeLa-Zellen stimuliert, 
während der EP3 spezifische Antagonist (L-798,106) die Expression in CaSki-Zellen inhibiert, 
ohne die EP1 Expression zu beeinflussen. Gleichzeitig wurde die Expression von 
phosphorylierten extrazellulären signal-regulierten Kinasen (ERK1/2) durch Sulprostone  
hoch-, durch L-798,106 hingegen herabreguliert. Sulprostone erhöhte das PAI-1 Level im 
Überstand sowohl bei CaSki- als auch bei HeLa-Zellen durch p-ERK1/2 und p53, was eine 
mögliche Korrelation zwischen dem EP3 Signalweg und dem Plasminogen-aktivierenden 
System in der Tumorentwicklung impliziert. In vivo Studien zeigten, dass die Überexpression 
von uPAR mit einer schlechteren Prognose bei Patientinnen mit Cervixkarzinom (FIGO III und 
IV) assoziiert ist, was suggeriert, dass uPAR, unabhängig vom EP3 Rezeptor, womöglich ein 
neues therapeutisches Ziel darstellt. L-798,106 konnte, als womöglich vielversprechende 
Substanz in der Therapie des Cervixkarzinoms, insbesondere des squamösen Subtyps, die 
Expression sowohl von EP3 als auch von uPAR in CaSki-Zellen verringern. 
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7.2 Die Rolle des EP3 Signalwegs im Pathomechanismus von rezidivierenden 
Spontanaborten 
In eine Studie über rezidivierende Spontanaborte (RSA) haben wir bestätigt, dass in 
stromalen Zellen der Dezidua bei Patienten mit ungeklärten Fällen von RSA ein erhöhter 
COX-2 Spiegel gefunden wurde. PGE2 hat in Kombination mit dem EP3-Rezeptor im 
extravillösen Trophoblast zu einer verringerten Produktion von β-hCG und Progesteron via 
Gi1 und AC geführt, was letztendlich zu einem reduzierten cAMP Spiegel und einer 
verringerten Aktivität der PKA beiträgt. Wir haben ebenfalls Interaktionen zwischen dem 
EP3-Signalweg und dem Plasminogen-aktivierenden System im Pathomechanismus 
rezidivierender Spontanaborte nachweisen können. Aktiviertes EP3/Gi1 kann die PAI-1 
Genexpression durch eine Stimulation von p-ERK1/2 und p53 verstärken. Eine hochregulierte 
Produktion von PAI-1 kann den Abbau der extrazellulären Matrix verhindern, was zu einer 
intervillösen Fibrinablagerung in der maternal-fetalen Schnittstelle beiträgt. Die herab 
regulierte Sekretion von β-hCG und Progesteron sowie die erhöhte Expression von PAI-1 
konnte die Einnistung des Trophoblasten und die Plazentation verhindern, was einen 
Abbruch der Schwangerschaft verursacht. Wir haben herausgefunden, dass der EP3-
Antagonist L-798,106 die EP3-Expression herabsetzt ohne den β-hCG Spiegel in JEG3 Zellen 
zu beeinflussen, was L-798,106 zu einem potentiellen Kandidaten in der Therapie von RSA 
macht. 
    Zusammenfassend spielt der EP3 Signalweg über p-ERK1/2 und PAI-1 eine vitale Rolle 
sowohl in der Entstehung des Cervixkarzinoms als auch im Pathomechanismus von 
Spontanaborten. Ein starker Zusammenhang zwischen dem EP3-Signalweg und dem 
Plasminogen-aktivierenden System existiert in beiden Krankheitsbildern, wobei L-798,106 
effektiv die Schlüsselfaktoren in ihrer Interaktion inhibiert. Zukünftige Studien sollten diesen 
Ansatz auf ein Tiermodell übertragen, um den Effekt von L-798,106 oder anderen 
spezifischen EP3 Antagonisten auf die Inhibition entzündlicher Reaktionen im 
Cervixkarzinom und in rezidivierenden Aborten zu untersuchen. Ein besonderes Augenmerk 
sollte zusätzlich auf die Membranrezeptoren PGE2 (EP1, 2 und 4) und auf andere Mitglieder 
der Gi-Familie (Gi2 und Gi3) im Hinblick auf rezidivierende Aborte und die Entstehung von 
Malignomen gelegt werden. 
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